 
 
A Randomized, Multi center, Phase III Trial of 
Tacrolimus/Methotrexate versus Post -Transplant 
Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in 
Non-Myeloablative/ Reduced Intensity Conditioning 
Allogeneic Peripheral Blood Stem Cell Transplantation  
Study Chairpersons  
Javier B olaños-Meade, MD1 and Shernan Holtan, MD2 
 
 
Companion Study: Microbiome and Immune Reconstitution 
in Cellular Therapies and Hematopoietic Stem Cell 
Transplantation (Mi -Immune)  
Study Chairpersons  
Leslie S. Kean MD, PhD15, Miguel -Angel Perales, MD13, and Ami Bhatt MD, PhD12 
 
 
(Posted on ClinicalTrials.gov as NCT # 03959241 ) 
BMT CTN Protocol 1703 /1801  
Version 4.0 
 
Sponsored by the National Institutes of Health  
National Heart, Lung, and Blood Institute  
National Cancer Institute  
 
 
 
 
 
1703 Protocol Team:
Monzr M. Al Malki, MD3 
Kristy Applegate, MBA4 
Nancy DiFronzo, PhD5 
Yvonne Efebera, MD , MPH6 
Raphael Fraser, PhD7 
Mahasweta Gooptu, MD8 
Lori A. Henderson, PhD 10 
Mehdi Hamadani, MD7 
Carrie Kitko, MD9 Eric Leifer, PhD5 
Michael Martens, PhD4 
 
Viji Ramachandran4 
Ran Reshef, MD11 
Andrew Rezvani, MD12 
Brian Shaffer, MD13 
Melhem Solh, MD14 
Janny Yao3?
 
 
1801 P rotocol Team:
Merav Bar , MD16     John Levine , MD20 
Brandi Bratrude , PMP, CCRP15   Brent Logan, PhD7 
Saurabh Chhabra , MD7    Hemant Murthy , MD21 
Sung Choi , MD17     Armin Rashidi , MD, PhD2 
William Clark , MD, MS18    Marcie Riches , MD, MS22 
Suman R. Das , PhD9     Wael Saber, MD, MS7 
Mary Horowitz, MD, MS7    Karam jeet Sandhu , MD3 
Rob Jenq , MD19     Ashley Spahn23 
Rick Jones , MD1     Anthony Sung , MD24 
 
 
1Johns Hopkins University  
2University of Minnesota  
3City of Hope  
4The Emmes Company  
5National, Heart, Lung and Blood 
Institute  
6Ohio State University  
7Medical College of Wisconsin  
8Dana Farber Cancer Institute  13Memorial Sloan Kettering Cancer Center  
14 Northside Hospital  
15Boston Children’s Hospital  
16Fred Hutchinson Cancer Research 
Center  
17Univers ity of Michigan  
   18Virginia Commonwealth University  
  19MD Anderson Cancer Center  
  20Mount Sinai
 9Vanderbilt University       21Mayo Clinic  - Florida  
 10National Cancer Institute       22University of North Carolina  
 11Columbia University       23National Marrow Donor Program  
 12Stanford University        24Duke University  
 
 
 
 
_____________________________ ____   ______________________________ _____  
Approval Signature (Protocol Chair/Officer)    Approval Signature (Protocol Chair/Officer)  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
ii PROTOCOL SYNOPSIS  
 
A Randomized, Multi center Phase III Trial of Tacrolimus/Methotrexate versus Post -Transplant 
Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative / Reduce d 
Intensity Conditioning Allogeneic Peripheral Blood Stem  Cell Transplantation  
 
Co-Principal Investigator s: Javier Bolaños -Meade, MD and Shernan Holtan, MD  
 
Study Design:  The study is designed as a randomized, phase III, multicenter  trial 
comparing two acute graft -versus -host disease (aGVHD) 
prophylaxis regimens: tacrolimus / methotrexate (Tac/MTX) 
versus pos t-transplant cyclophosphamide / tacrolimus / 
mycophenolate mofetil (PTCy/Tac/MMF) in the setting of 
reduced intensity conditioning (RIC) allogeneic peripheral blood 
stem  cell (PBSC) transplantation . 
 
Primary Objective:  The primary objective of the trial is  to compare 1 year GVHD -
free, relapse -free survival (GRFS) between the  two GVHD 
prophylaxis regimens . An event for this time —to-event outcome 
is defined as grade III -IV aGVHD, chronic GVHD  requiring 
systemic immune suppression , disease relapse or progressi on, or 
death by any cause.  
 
Secondary Objective:  Secondary objectives are to describe for each treatment arm rates 
of grade II -IV and III -IV aGVHD, rates of Minnesota high risk 
aGVHD, chronic GVHD, immunosuppression -free survival at 1 
year, hematologic re covery (neutrophil and platelet), donor cell 
engraftment, disease relapse or progression, transplant -related 
mortality, rates of grade 3+ toxicity according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0, 
incidence of grade 2 -3 infections, immune reconstitution, and 
overall survival.   
 
Eligibility Criteria:   
Eligible patients are at least 18.0 years of age undergoing 
allogeneic PBSC transplant for the treatment of acute leukemia 
and chronic myelogenous leukemia with no circulating blasts and 
less than 5% blasts in the bone marrow; or 
myelodysplasia/chronic mye lomonocytic leukemia with no 
circulating blasts and less than 10% blasts in the bone marrow; 
chronic lymphocytic leukemia/small lymphocytic lymphoma, 
follicular lymphoma, Hodgkin lymphoma, diffuse large B cell 
lymphoma, mantle cell lymphoma, peripheral T -cell lymphoma, 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
iii angioimmunoblastic T -cell lymphoma and anaplastic large cell 
lymphoma sensitive to chemotherapy who are eligible for an 
allogeneic hematopoietic cell transplantation (HCT). Patients are 
eligible only if receiving a RIC regimen.  
 
 
 Patients must have a related or unrelated PBSC  donor.  Sibling 
donor must be a 6/6 match for HLA -A and HLA -B at 
intermediate or higher resolution, and DRB1 at high resolution 
using DNA -based typing ; must be willing to donate peripheral 
blood stem cells ; and meet institutional criteria for donation.  
Unrelated donor must be a 7/8 or 8/8 match at HLA -A, -B, -C, 
and -DRB1 at high resolution using  DNA -based typing ; must be 
willing to donate PBSCs ; and be medically eligible to donate 
stem cells according to NMDP c riteria.   
 
Treatment Description:  Patients will be randomized to receive one of 2 specified GVHD 
prophylaxis regimens: Tac/MTX or PTCy/Tac/MMF.  MTX will 
be dosed at 15 mg/m2 Day +1, and 10 mg/m2 Days +3, +6, and 
+11. PTCy will be dosed at 50 mg/kg on Days +3 and +4, 
followed by Tac/MMF.  MMF will be dosed at 15 mg/kg every 8 
hours from Day +5 to Day +35. 
 
Accrual Objective:  The clinical trial will enroll 428 patients, or 214 per arm . 
 
Accrual Period:  The estimated accrual period is 36 months . 
 
Study Duration:  Patients will be followed for 1 year post -PBSC transplant . 
 
Interim Analysis:  The study will include one interim analysis for efficacy , for the 
primary endpoint at the time when the required total number of 
events is reached.  Z test statistic for  comparing the two treatment 
arms will be compared to the critical values and results will be 
reviewed by the NHLBI -appointed Data and Safety Monitoring 
Board (DSMB). If the test statistic is outside the continuation 
range, the DSMB will be consulted on th e discontinuation of the 
trial. 
 
Stopping Guidelines:  Monitoring of the key safety endpoint of death will be conducted.  
The rate of overall mortality will be monitored up to Day 100 
post-randomization separately in each of the 2 treatment arms. 
Each month,  the null hypothesis that the Day 100  mortality rate 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
iv is less than or equal to 1 5% is tested using a truncated Sequential 
Probability Ratio Test (SPRT) for censored exponential data.  
 
Correlative Studies:  Completed through the Mi-Immune  study (Appendix J), with 
additional blood samples processed and stored for future 
research.  
 
Companion Study:  Microbiome and Immune Reconstitution in Cellular 
Therapies and Hematopoietic Stem Cell Transplantation  
(Mi-Immune)  
 
Co-Principal Investigator:  Leslie S. Kean MD, PhD, Miguel -Angel Perales, MD, and Ami 
Bhatt MD, PhD  
Primary Objective:  The goal of this protocol is to test the primary hypothesis that the 
engraftment stool microbiome diversity predicts one -year non -
relapse mortality in patients undergoing reduced inten sity 
allogeneic HCT.  Our study will be powered to test this 
hypothesis. Patients will be primarily recruited through co -
enrollment on BMT CTN 1703.  
Secondary Objectives:  To establish a cohort of biologic samples and a linked clinical 
and molecular dataset  from patients and donors from  BMT CTN 
1703. The product of this study will be a shared biospecimen and 
data resource for conducting future allogeneic HCT mechanistic 
studies.  
To study the diversity of the immune repertoire post -transplant 
and correlate w ith clinical outcomes, as well as study the impact 
on immune recovery of the method of GVHD prophylaxis and 
other patient and transplant factors.  
 To study the diversity and composition of the gut microbiome 
post-transplant and correlate with clinical outc omes, as well as 
study the impact on the microbiome of the method of GVHD 
prophylaxis and other patient and transplant factors.  
Eligibility Criteria:  Eligible patients are at least 18 years of age and enrolled on the 
BMT CTN 1703 PROGRESS III study.  Eligib le donors are at 
least 18 years of age.  
Treatment Description:  Conditioning regimens, GVHD prophylaxis, and other 
supportive care will be those described in BMT CTN 1703.  
Accrual Objective:  A minimum of 300 patients will be enrolled (in collaboration 
with protocol BMT CTN 1703).  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
v Accrual Period:  The estimated accrual period is 3 6 months . 
Study Duration:  Patients will be followed clinically for 12 months post -HCT; 
long-term follow -up data will be collected through usual 
procedures of the Center for International Blood and Marrow 
Transplant Research (CIBMTR).  A 24-month  biological sample 
will be collected as well.  
 
  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
vi Outline of Treatment Plan  
 
 
 
 
 
  Age 18 .0 years  and older  
Controlled Malignant Diseases  
RIC 
Related or Unrelated PBSC Donor  
Tac/MTX  Tac/MMF/  
Cyclophosphamide  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
vii TABLE OF CONTENTS  
1 BACKGROUND AND RATIONALE  ................................ ................................ ..............  1-1 
1.1 Introduction  ................................ ................................ ................................ .................  1-1 
1.2 Cyclop hosphamide, Tacrolimus, and Mycophenolate Mofetil (PTCy/Tac/MMF)  1-2 
1.2.1  Rationale of Post -transplant Cyclophosphamide  ................................ ...................  1-2 
1.2.2  Post-transplant Cyclophosphamide in Alternative Donor Transplantation  ...........  1-2 
1.2.3  Post-transplant Cyclophosphamide as GVHD Prophylaxis after PBSC 
transplantation  ................................ ................................ ................................ ....... 1-3 
1.3 Benchmark Analysis and Composite Endpoint  ................................ ........................  1-3 
1.4 Studies of the Microbiome and Immune Reconstitution in Transplant Patients  .. 1-6 
1.4.1  Microbiome Studies  ................................ ................................ ...............................  1-6 
1.4.2 Protective Immunity ................................ ................................ ...............................  1-7 
1.4.3  Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic 
Stem Cell Transplantation (Mi -Immune)  ................................ ..............................  1-8 
1.5 Rationale for a Randomized Trial  ................................ ................................ .............  1-8 
2 sTudy design  ................................ ................................ ................................ ........................  2-1 
2.1 Study Overview  ................................ ................................ ................................ ...........  2-1 
2.2 Hypothesis and Specific Objectives  ................................ ................................ ...........  2-1 
2.2.1  Primary Hy pothesis  ................................ ................................ ................................  2-1 
2.2.2  Study Objectives  ................................ ................................ ................................ .... 2-1 
2.3 Patient Eligibility  ................................ ................................ ................................ .........  2-2 
2.3.1  Inclusion Criteria  ................................ ................................ ................................ ... 2-2 
2.3.2  Exclusion Criteria  ................................ ................................ ................................ .. 2-3 
2.4 Treatment Plans  ................................ ................................ ................................ ..........  2-3 
2.4.1  Conditioning Regimens  ................................ ................................ .........................  2-4 
2.4.2  Hematopoietic Stem Cell Transplantation (HCT)  ................................ .................  2-7 
2.4.3  Tacrolimus/Methotrexate  ................................ ................................ .......................  2-7 
2.4.4  Tacrolimus/Mycophenolate Mofetil/Cyclophosphamide  ................................ ...... 2-8 
2.5 Supportive Care ................................ ................................ ................................ ...........  2-9 
2.5.1  Growth Factors ................................ ................................ ................................ ....... 2-9 
2.5.2  Blood Products  ................................ ................................ ................................ ....... 2-9 
2.5.3  Prophylaxis Against Infections  ................................ ................................ ..............  2-9 
2.5.4  Intravenous Immune Globulin (IVIG)  ................................ ................................ ... 2-9 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
viii 2.6 Participant Risks  ................................ ................................ ................................ .........  2-9 
2.6.1  Therapy Toxicities  ................................ ................................ ................................ . 2-9 
2.6.2  Tacrolimus  ................................ ................................ ................................ .............  2-9 
2.6.3  Meth otrexate  ................................ ................................ ................................ ........  2-10 
2.6.4  Mycophenolate mofetil (MMF)  ................................ ................................ ...........  2-10 
2.6.5  Cyclophosphamide  ................................ ................................ ...............................  2-11 
2.6.6  Busulfan  ................................ ................................ ................................ ...............  2-11 
2.6.7  Fludarabine  ................................ ................................ ................................ ..........  2-12 
2.6.8  Melphalan  ................................ ................................ ................................ ............  2-12 
2.6.9  Total Body Irradiation (TBI)  ................................ ................................ ...............  2-12 
2.7 Study Drug Supply  ................................ ................................ ................................ .... 2-13 
3 STUDY ENDPOINTS  ................................ ................................ ................................ ........  3-1 
3.1 Primary Endpoint  ................................ ................................ ................................ ....... 3-1 
3.2 Secondary Endpoints  ................................ ................................ ................................ .. 3-1 
3.2.1  Acute GVHD  ................................ ................................ ................................ .........  3-1 
3.2.2  Chronic GVHD  ................................ ................................ ................................ ...... 3-1 
3.2.3  Systemic Immunosuppression -free Survival  ................................ .........................  3-1 
3.2.4  Hematologic Recovery ................................ ................................ ...........................  3-2 
3.2.5  Donor Cell Engraftment  ................................ ................................ .........................  3-2 
3.2.6  Disease Relapse or Progression  ................................ ................................ .............  3-2 
3.2.7  Transplant -related Mortality  ................................ ................................ ..................  3-3 
3.2.8  Toxicity  ................................ ................................ ................................ ..................  3-3 
3.2.9  Infections ................................ ................................ ................................ ................  3-3 
3.2.10  Disease -Free Survival  ................................ ................................ ............................  3-4 
3.2.11  Overall Survival  ................................ ................................ ................................ ..... 3-4 
3.2.12  PTLD ................................ ................................ ................................ ......................  3-4 
3.2.13  Patient -Reported Outcomes (PRO)  ................................ ................................ ........  3-4 
3.3 Endpoint Review Process  ................................ ................................ ...........................  3-4 
4 PATIENT ENROLLMENT AND EVALUATION  ................................ .........................  4-1 
4.1 Approaching Patients, Eligibility Screening and Obtaining Consent  ....................  4-1 
4.2 Transplant Protocol Registration  ................................ ................................ ..............  4-1 
4.3 Randomizat ion ................................ ................................ ................................ .............  4-1 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
ix 4.4 Treatment Scheduling  ................................ ................................ ................................ . 4-2 
4.5 Patient Evaluation  ................................ ................................ ................................ ....... 4-2 
4.6 Study Monitoring  ................................ ................................ ................................ ........  4-2 
4.6.1  Patient Assessments  ................................ ................................ ...............................  4-3 
4.6.2  Pre-transplant Evaluations  ................................ ................................ .....................  4-5 
4.6.3  Post-transplant Evaluations  ................................ ................................ ....................  4-6 
4.6.4  Criteria for Forms Submission  ................................ ................................ ...............  4-7 
4.6.5  Reporting Patient Deaths  ................................ ................................ .......................  4-7 
4.7 Adverse Event Reporting Requirements  ................................ ................................ .. 4-7 
4.7.1  Definitions ................................ ................................ ................................ ..............  4-7 
4.7.2  BMT CTN Adverse Event Reporting Guidelines  ................................ ..................  4-8 
4.8 CIBMTR Data Reporting  ................................ ................................ ...........................  4-9 
5 STATISTICAL CONSIDERATIONS  ................................ ................................ ............  5-10 
5.1 Study Design  ................................ ................................ ................................ ..............  5-10 
5.1.1  Accrual  ................................ ................................ ................................ .................  5-10 
5.1.2  Randomization  ................................ ................................ ................................ ..... 5-10 
5.1.3  Primary Endpoint  ................................ ................................ ................................ . 5-10 
5.1.4  Primary Hypothesis  ................................ ................................ ..............................  5-10 
5.2 Sample Size and Power Considerations  ................................ ................................ .. 5-11 
5.3 Interim Analysis and Stopping Guidelines  ................................ .............................  5-11 
5.3.1  Interim Analysis for Efficacy  ................................ ................................ ...............  5-11 
5.3.2  Operating Characteristics of the Design  ................................ ..............................  5-12 
5.3.3  Guidelines for Safety Monitoring  ................................ ................................ ........  5-13 
5.4 Demographic and Baseline Characteristics  ................................ ............................  5-14 
5.5 Analysis Populations  ................................ ................................ ................................ . 5-14 
5.5.1 Primary Population  ................................ ................................ ..............................  5-14 
5.5.2  Safety Population  ................................ ................................ ................................ . 5-15 
5.5.3  Transplant Population  ................................ ................................ ..........................  5-15 
5.6 Analysis of Primary Endpoint  ................................ ................................ ..................  5-15 
5.7 Analysis of Secondary Endpoints  ................................ ................................ ............  5-15 
5.7.1  Acute GVHD  ................................ ................................ ................................ ....... 5-15 
5.7.2  Chro nic GVHD  ................................ ................................ ................................ .... 5-15 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
x 5.7.3  Systemic Immunosuppression -Free Survival  ................................ ......................  5-16 
5.7.4  Hematologic Recovery ................................ ................................ .........................  5-16 
5.7.5  Donor Cell Engraftment  ................................ ................................ .......................  5-16 
5.7.6  Disease Relapse or Progression  ................................ ................................ ...........  5-16 
5.7.7  Transplant -related Mortality  ................................ ................................ ................  5-16 
5.7.8  Toxicity  ................................ ................................ ................................ ................  5-16 
5.7.9  Infections ................................ ................................ ................................ ..............  5-17 
5.7.10  Disease -free Survival  ................................ ................................ ...........................  5-17 
5.7.11  Overall Survival  ................................ ................................ ................................ ... 5-17 
5.7.12  Post-Transplant Lymphoproliferative Disease (PTLD)  ................................ ....... 5-17 
5.7.13  Patient -Reported Outcomes (PRO)  ................................ ................................ ...... 5-17 
5.8 Safety Analysis  ................................ ................................ ................................ ...........  5-17 
APPENDIX A: Human Subjects  
APPENDIX B: Chimerism Assessment  
APPENDIX C: Derivation of a Sequential Test Statistic for Censored Exponential Data  
APPENDIX D: Karnofsky Performance Status Scale  
APPENDIX E: HCT -Specific Comorbidity Index Score  
APPENDIX F: Disease Risk Index  
APPENDIX G: Diagnosis and Severity Scoring for Acute and Chronic GVHD  
APPENDIX H: Patient Reported Outcome Questions  
APPENDIX I: References  
APPENDIX J: Mi -Immune S tudy  
 
BMT CTN 1801  
1 Background and Significance  ................................ ................................ ...............................  1 
2 Study Design  ................................ ................................ ................................ ...........................  2 
2.1 Study Overview  ................................ ................................ ................................ ..............  2 
2.2 Hypothesis and Objectives ................................ ................................ .............................  2 
2.2.1  Hypothesis ................................ ................................ ................................ .................  2 
2.2.2  Objectives  ................................ ................................ ................................ .................  2 
2.3 Eligibility Criteria for Enrollment ................................ ................................ ................  3 
2.4 Treatment Plan  ................................ ................................ ................................ ...............  4 
3 Study Endpoints and Definitions  ................................ ................................ .........................  5 
3.1 Primary Endpoint  ................................ ................................ ................................ ..........  5 
3.2 Secondary Endpoints  ................................ ................................ ................................ ..... 5 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
xi 3.2.1  Clinical Endpoints  ................................ ................................ ................................ ..... 5 
3.2.2  Infection  ................................ ................................ ................................ ....................  5 
3.2.3  Correlat ive endpoints  ................................ ................................ ................................  5 
3.2.3.1  Microbiome  ................................ ................................ ................................ ...............  5 
3.2.3.2  T cell Repertoire  ................................ ................................ ................................ ....... 5 
4 Patient Evaluation  ................................ ................................ ................................ .................  6 
4.3 Collection of Research Samples  ................................ ................................ ...........  10 
4.3.1  Study Blood Draws  ................................ ................................ ................................ . 10 
4.3.2     Stool Samples  ................................ ................................ ................................ ...........  10 
4.3.3     Urine Samples  ................................ ................................ ................................ ..........  10 
5 Statistical Considerations ................................ ................................ ................................ .... 11 
5.1 Study Overview  ................................ ................................ ................................ ............  11 
5.1.1  Accr ual ................................ ................................ ................................ ....................  11 
5.1.2  Randomization  ................................ ................................ ................................ ........  11 
5.1.3  Primary Endpoint  ................................ ................................ ................................ .... 11 
5.1.4  Primary Objective  ................................ ................................ ................................ ... 11 
5.1.5  Sample Size and Power Considerations  ................................ ................................ .. 11 
5.2 Interim Analysis and Pausing Guidelines  ................................ ................................ .. 12 
5.3 Demographic and Baseline Characteristics  ................................ ...............................  12 
5.4 Analysis Populations  ................................ ................................ ................................ .... 12 
5.5 Analysis Plan  ................................ ................................ ................................ .................  13 
5.5.1  Analysis of the Primary Objective:  Compare NRM within 1 year between groups 
defined by engraftment stool microbiome diversity.  ................................ ..............  13 
5.5.2  Analysis of the Secondary Objectives  ................................ ................................ .... 13 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-1 CHAPTER 1  
 
1 BACKGROUND AND RATIONALE  
1.1 Introduction  
Acute Graft -versus -Host -Disease (GVHD) is an important cause of morbidity and mortality after 
allogeneic hematopo ietic cell transplantation ( HCT ). Clinically significant grade II -IV acute 
GVHD occurs in 34 -40% of patients undergoing HLA -matched related donor HCT , 47-52% of 
HLA -matched unrelated donor HCT , and is further increased in those lacking  
HLA -matched donors.1,2,3,4 
Acute GVHD is mediated by donor -derived T cells that are reactive against recipient antigens 
expressed in the context of the major histocompatibility complex (MHC or HLA). These antigens, 
termed minor histocompatibility antigens (mHA), are small peptides with immunogenic single 
nucleotide polymorphisms (SNPs) capable of eliciting potent T cell immune responses upon 
presentation by antigen presenting cells (APCs).  A number of these mHAs have been identified.5 
In fact, mismatches of known mHA among HLA identical donor -recipient pairs have been 
associated with the development of acute GVHD after stem cell transplantation.6  
Approximately 40% of patients with acute GVHD will have durable responses to corticosteroid 
therapy.7 The prognosis of the 60% of patients without long -lasting response is poor.8 A strategy 
that minimizes the incidence of acute GVHD, without other adverse effects, would be an effective 
approach to improve survival after allogeneic transplantation.  
Acute GVHD incidence can be d ecreased with various pharmacologic agents.  Early transplants 
were done using post -transplant methotrexate to prevent GVHD; in the 1980s cyclosporine was 
shown to be superior to methotrexate and in 1986 the combined use of cyclosporine and 
methotrexate was  shown to be superior to single agent prophylaxis.9 More recently, other 
calcineurin -inhibitors, such as tacrolimus have been developed as acute GVHD prophylactic 
agents due to favorable toxicity profiles in comparison with cyclosporine.10,11 
Phase III tri als comparing tacrolimus/methotrexate (Tac/MTX) versus cyclosporine/methotrexate 
for related and unrelated donors have been performed. In the unrelated donor setting, the incidence 
of grade II -IV acute GVHD was 56% among the 46 patients randomized to tacro limus arm versus 
74% among the 63 patients randomized to cyclosporine arm.12 The combination of 
tacrolimus/methotrexate remains the standard for acute GVHD prophylaxis, despite its limited 
efficacy. Hence for many years, a calcineurin inhibitor -based doubl et has been considered the 
standard of care for acute GVHD prophylaxis.   
In order to test novel regimens incorporating agents promising in the phase II setting, BMT CTN 
1203 was completed.  This phase II multicenter trial randomly assigned patients (pts) 1: 1:1 to 
Tac/MTX /maraviroc 300mg PO BID Day -3 to +30; Tac/MTX/bortezomib 1.3mg/m2 on Days 
+1, +4, and +7; or post -transplant cyclophosphamide (PTCy) 50mg/kg/day on Days +3 and +4 
plus Tac/MMF(mycophenolate mofetil), each compared with a nonrandomized prosp ective 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-2 contemporaneous Tac/MTX treated control cohort. Pts aged 18 -75 with hematologic malignancies 
eligible for RIC allo HCT  were accrued. All pts received peripheral blood stem cell (PBSC) grafts 
from 6/6 HLA matched related or 7 -8/8 HLA matched unrelated  donors. Controls had the same 
eligibility, but enrollment was done at centers not participating in the trial.   
In BMT CTN 1203, the regimen of PTCy/Tac/MMF was the most promising compared to controls 
(detailed in later paragraphs) and thus has been select ed for a randomized phase III study in 
comparison with Tac/MTX in BMT CTN 1703.  
1.2 Cyclophosphamide, Tacrolimus, and Mycophenolate Mofet il 
(PTCy/Tac/MMF)  
1.2.1 Rationale of Post -transplant Cyclophosphamide  
High dose cyclophosphamide is a potent immunosuppressor that has been successfully used to 
prevent GVHD in unrelated, HLA -matched sibling and haploidentical bone marrow/PBSC 
transplants in single center as well as in multicenter  studies.13,14,15,16,17 ,50 Cyclophosphamide 
administered early post HCT  preferentially kills allo -reactive T cells while sparing resting, non 
allo-reactive T cells leading to suppression of GVHD as well as graft rejection.18 The paragraphs 
that follow highlight the growing experience with PTCy as GVHD prophylaxis.  
1.2.2 Post-transplant Cyclophosphamide in Alternative Donor Transplantation  
Based on promising pre -clinical results at Johns Hopkins, a Phase I/II clinical trial of 
haploi dentical BMT to treat high -risk hematologic malignancies was initiated in 1999.  Following 
a non -myeloablative regimen of fludarabine, cyclophosphamide, and low -dose total body 
irradiation (TBI), GVHD prophylaxis consisted of cyclophosphamide (Cy) given on Days +3 and 
+4 post -transplant, tacrolimus, and mycophenolate mofetil (MMF).15 Primary graft failure 
occurred in 13% of patients, and was fatal due to infection in one patient in whom autologous 
hematopoiesis failed to occur.  In general, complete T -cell en graftment was observed by Day +28 
or the grafts were rejected.  Cumulative incidences of grades II -IV and grades III -IV acute GVHD 
by Day 200 were 34% and 6%, respectively.  There was lower incidence of extensive chronic 
GVHD among recipients of two versus o ne dose of post -transplantation Cy (5% versus 25%; 
p=.05).  There was no difference in the incidence of severe acute GVHD with one or two doses of 
post-transplant Cy.  The cumulative incidences of non -relapse mortality and relapse at 1 year were 
15% and 51%,  respectively. Actuarial overall and event -free survivals (EFS) at two years after 
transplantation were 36% and 26%, respectively.  Patients with lymphoid malignancies appeared 
to have an improved EFS compared to those with myeloid malignancies (p=.02).  
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) sponsored a multicenter  
Phase II trial of haploidentical BMT (BMT CTN 0603) for high -risk hematologic malignancies 
modeled after the Hopkins approach.  This was published along with a similar st udy using cord 
grafts without post -transplant Cy (BMT CTN 0604).13 The 1 -year probabilities of overall and 
progression -free survival were 54% and 46% after cord transplantation and 62% and 48% after 
haploidentical bone marrow transplantation.  The Day +56 c umulative incidence of neutrophil 
recovery was 94% after dUCB and 96% after haploidentical marrow.  The 100 -day cumulative 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-3 incidence of grade II -IV acute GVHD was 40% with cord blood and 32% with haploidentical bone 
marrow.  The 1 -year cumulative incidences of non -relapse mortality and relapse after cord 
transplantation were 24% and 31%, respectively; corresponding rates after haploidentical bone 
marrow transplantation were 7% and 45%.  
1.2.3 Post-transplant Cyclophosphamide as GVHD Prophylaxis after PBSC transplant ation  
Post-transplant Cy as GVHD prophylaxis was developed initially for haploidentical BM 
transplantation after nonmyeloablative conditioning but, recently, several studies have extended 
the approach to PBSC transplantation.  To date, haploidentical nonabl ative transplantation with 
post-transplant Cy has used bone marrow as the graft source.  Use of PBSC instead of marrow may 
allow wider applicability of this approach but there is concern about higher risks of acute and 
chronic GVHD due to the 5 -10-fold high er number of T -cells in the allograft. Groups in Houston 
and Seattle/London reported small studies in which PBSC were substituted for BM with post -
transplant Cy in the haploidentical donor setting.16,19  In both studies, the incidences of severe 
acute GVHD , chronic GVHD and non -relapse mortality at 1 year with PBSC were comparable to 
the rates seen with BM.  A recent large series compared clinical outcomes in 481 patients receiving 
haploidentical bone marrow (BM) grafts versus 190 patients receiving haploide ntical PBSC grafts.  
There were no significant differences in OS or NRM, but leukemia patients receiving BM had a 
lower risk of acute and chronic GVHD (HR = 0.45, p<0.001 and HR = 0.35, p<0.001 respectively), 
and patients with leukemia receiving BM had a hi gher risk of relapse (HR 1.73, p=0.002).20  
PTCy has been extended beyond haploidentical donor grafts and into matched related/unrelated 
PBSC transplantation in recent reports. The Seattle group published experience with 
PTCy/cyclosporine/MMF as GVHD proph ylaxis in the myeloablative transplantation setting, with 
previously tested regimen that showed excellent rates of engraftment (>97%), low relapse at 2 
years (17%), low 2 -year non -relapse mortality (14%), no grade III -IV acute GVHD, and low rates 
of chr onic GVHD (16%).21 Moiseev et al described similar outcomes in a prospective study, with 
<10% grade III -IV acute GVHD and non -relapse mortality <20%.50  In BMT CTN 1203, a reduced 
intensity setting, PTCy/Tac/MMF showed the most favorable results compared to  controls (details 
in 1.3).  Thus, experience and interest in extending PTCy in to the matched PBSC transplantation 
setting continues to grow.  
1.3 Benchmark Analysis and Composite Endpoint  
In order to better evaluate the efficacy of novel approaches for GVHD pr ophylaxis, a benchmark 
analysis was performed using data from the Center for International Blood and Marrow Transplant 
Research (CIBMTR) for patients who received a RIC HCT .  
The CIBMTR maintains an outcomes registry that prospectively collects data from a ll centers 
performing allogeneic HCT s and almost all centers performing autologous HCT s in the United 
States and about 100 non -US centers. Centers must report all consecutive patients and provide 
longitudinal follow -up on those patients according to set ti melines that include a pre -transplant 
report, a 100 -day report, a 6 -month report and an annual report through 6 years post -transplant 
followed by a biannual report in perpetuity. Data are reported on two tracks: a “Transplant 
Essential Data” track and a “C omprehensive Report Form” track.  Centers provide a pretransplant 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-4 Transplant Essential Data form for all patients.  Data from this form are used to select patients for 
the Comprehensive Report Form track using a weighted random selection that over selects pa tients 
with rare diseases or procedures or for the purposes of specific studies.  For example, most patients 
on BMT CTN trials are selected for the Comprehensive Report Form track so that data collected 
by the CIBMTR can supplement clinical trial data colle cted through AdvantageEDC or Advantage 
eClinical and can allow for long -term follow -up of trial patients for specific late effects of 
treatment. Longitudinal data are collected for patients on both the Transplant Essential Data and 
Comprehensive Report For m Track; the data differ in quantity and granularity.  Data quality is 
ensured by computerized error checks and on -site audits.  
The objective of the benchmark analysis was to select promising approaches to be further studied 
and to explore novel endpoints t hat could not only assess GVHD, but also the complex 
relationships between relapse and GVHD as well as prolonged use of immune suppression. The 
control population selected from the CIBMTR database was comprised of patients who received 
HCT  in a US center f rom 2006 to 2009 and who received tacrolimus and methotrexate as their sole 
GVHD prophylaxis. Data from single institution studies of the two agents to be tested in this 
protocol were also studied. Populations differed according to disease, donor, conditio ning 
intensity, disease risk and patient age. Each institutional cohort was compared with the CIBMTR 
controls, adjusting for differences in baseline populations using multivariate regression techniques.  
Table 1.3A summarizes the results of both univariate and multivariate analyses for the 2 arms 
proposed in BMT CTN 1703.   
Table 1 .3A: Univariate  and Multivariate Results from the Benchmark Analysis  
Outcome  Tac+MTX Control  
(95%CI)  PTCy  
(95%CI)  
Grade III -IV Acute 
GVHD  HR 
 1.00 0.90 
(0.58 -1.4) 
Incidence at 6 mo  
(95%CI)  25% 
(23-26%)  23% 
(15-33%)  
CGVHD  HR 
 1.00 0.24 
(0.14 -0.41)  
Incidence at 12 mo  
(95%CI)  45% 
(43-46%)  13% 
(7-20%)  
Overall Survival  HR 
 1.00 1.07 
(0.82 -1.4) 
Probability at 12 mo  
(95%CI)  60% 
(58-61%)  57% 
(47-66%)  
Disease free survival  HR 1.00 1.21 
(0.94 -1.56)  
Probability at 12 mo  
(95%CI)  52% 
(51-53%)  46% 
(37-55%)  
HR=Hazard Ratio, CI=Confidence Interval. The event for overall survival was death and the event for disease free survival was  death or 
relapse. A hazard ratio (HR) greater than 1 implies that a specific group has more events at any time compared to the Tac +MTX Control 
reference group (indicated by a HR of 1.00).  
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-5 We remain interested in evaluating a composite endpoint that would better reflect reductions in 
either or both acute and chronic GVHD as well as the sometimes opposite effects of reducing 
GVHD on t ransplant -related mortality and relapse.  In BMT CTN 1203, PTCy/Tac/MMF was the 
only study arm that showed an improved GVHD - Free-Relapse -Free Survival (GRFS) relative to 
controls.  The study design provided an 81 -87% power to identify a superior treatment i f 1-year 
GRFS was 15% better than control. One -sided testing was used. 92 pts were assigned to 
PTCy/Tac/MMF; 89 to Tac/MTX/bortezomib; 92 to MTX/Tac/maraviroc; and 224 controls 
received Tac/MTX. For the primary 1 -year GRFS endpoint, only the MMF/Tac/PTCy a rm was 
superior to control (p 0.04, Table 1.3B). The cumulative incidence of grade II -IV aGvHD through 
Day 180 was not different for each arm vs. control; however, for  grade III -IV aGvHD and GVHD -
free survival, PTCy/Tac/MMF was superior to control (p 0.006 , p 0.01 respectively) . While there 
was no difference in overall cGvHD incidence, for cGVHD requiring SIS, the PTCy/Tac/MMF 
arm was superior to control (p 0.04). Treatment -related mortality at 1 year was 11% for 
PTCy/Tac/MMF vs 16% in controls and 17% in the other 2 arms, but was not statistically different. 
There were no differences in engraftment, relapse/progression, and overall survival.  
Table 1.3B: Multivaria te Outcomes  
s  Controls  Bortezomib  Maraviroc  PTCy  
GRFS  HR (90% CI)  1 0.82 (0.62 -1.08)  1.02 (0.79 -1.32)  0.72 (0.54 -0.94)  
 P   0.2407  0.8689  0.0467  
 Adjusted 1 yr KM 
estimates  0.32 (0.26 -0.39)  0.42 (0.33 -0.54)  0.32 (0.23 -0.43)  0.46 (0.37 -0.57)  
aGvHD  II-IV HR (90% CI)  1 0.80 (0.53 -1.20)  0.98 (0.68 -1.43)  0.83 (0.56 -1.22)  
 P   0.3694  0.9578  0.4334  
 CuI at 180 days 
(90% CI)  31 (26 -36)%  26 (19 -34)%  32 (24 -40)%  27 (20 -35)%  
aGvHD III -IV HR (90% CI)  1 0.51 (0.25 -1.04)  0.58 (0.29 -1.15)  0.13 (0.03 -0.44)  
 P   0.1204  0.1945  0.0066  
 CuI at 180 days 
(90% CI)  13 (9 -16)%  8 (4-13)%  9 (4-14)%  2 (0-5)% 
cGvHD  HR (90% CI)  1 1.07 (0.76 -1.51)  1.23 (0.90 -1.70)  0.74 (0.51 -1.08)  
 P   0.7352  0.2717  0.2029  
 CuI at 1 yr (90% CI)  38 (32 -43)%  39 (30 -47)%  44 (35-53) 37 (20 -36)%  
cGvHD requiring 
immunosuppression  HR (90% CI)  1 0.70 (0.45 -1.07)  0.85 (0.57 -1.26)  0.57 (0.36 -0.89)  
 P   0.1749  0.5063  0.0413  
 CuI at 1 yr (90% CI)  32 (27 -37)%  22 (16 -30)%  27 (20 -35)%  19 (12 -26)%  
Relapse/progression  HR (90% CI)  1 0.94 (0.60 -1.46)  1.209 (0.80 -1.81)  1.24 (0.84 -1.83)  
 P   0.8188  0.4415  0.3458  
 CuI at 1 yr (90% CI)  25 (20 -30)%  22 (15 -30)%  28 (20 -36)%  27 (20 -35)%  
Treatment related 
mortality  HR (90% CI)  1 1.06 (0.63 -1.78)  0.97 (0.57 -1.65)  0.62 (0.34 -1.11)  
 P   0.8465  0.9327  0.1799  
 CuI at 1 yr (90% CI)  16 (12 -21)%  17 (11 -24)%  17 (11 -24)%  11 (6 -17)%  
Disease -free 
survival  HR (90% CI)  1 0.97 (0.70 -1.35)  1.14 (0.83 -1.57)  0.93 (0.68 -1.29)  
 P   0.9086  0.4685  0.7449  
 1 yr KM estimates  59 (53 -64)%  60 (52 -69)%  56 (47 -64)%  62 (53 -70)%  
GvHD free survival  HR (90% CI)  1 0.83 (0.62 -1.11)  0.98 (0.75 -1.28)  0.63 (0.46 -0.85)  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-6  P   0.3078  0.9130  0.0121  
 Adjusted 1 yr 
estimates (90% CI)  0.39 (0.33 -0.46)  0.46 (0.37 -0.58)  0.40 (0.31 -0.51)  0.56 (0.47 -0.67)  
 
1.4 Studies of the Microbiome and Immune Reconstitution in Transplant Patients  
1.4.1 Microbiome Studies  
The microbiome, consisting of a varied community of microbes (bacteria, viruses, fungi, 
microeukaryotes, and sometimes multicellular parasites), exists in niches across the human body. 
The skin, lung, nares, vagina, and gastrointestinal tract are among the  most heavily colonized, with 
the largest number of microorganisms inhabiting the colonic lumen. Intestinal microbiota interact 
with and regulate host immunity.26 While the majority of the over trillion organisms that live within 
a healthy human colon are nonpathogenic members of the phyla Firmicutes, Bacteroidetes, 
Actinobacteria, and Proteobacteria, alterations in the balance of these microorganisms have been 
associated with adverse outcomes ranging from GVHD and infection to relapse post -HCT.27 This 
clinical association between intestinal microorganisms and HCT outcomes has been investigated 
for decades – and has informed the still controversial practices of infe ction prophylaxis, gut 
decontamination, the “neutropenic diet,” and isolation of patients in laminar air flow rooms. 
Single -institution studies have demonstrated that low microbial diversity in the stool after 
allogeneic HCT is associated with poor surviva l .28,29 Additionally, specific alterations have been 
associated with increased risk of acute GVHD, infectious outcomes and most recently, relapse .30-
32 While these findings are compelling, most studies have been carried out in single institutions 
and thus  the generalizability of  these proposed microbial biomarkers is unclear. This is particularly 
important as there is known geographic variation of the intestinal microbiome and practice 
variability in antibiotic use for prophylaxis and treatment from instit ution to institution, in part due 
to different antibiograms.  
Growing understanding of the positive roles of the microbiome in regulating immune maturation 
in developing humans, maintenance of host barriers against pathogens, and nutrition suggest that 
the health of the microbiome must be carefully considered in allogeneic HCT patients.  
 
While a substantial investment was made by the NIH Common Fund in characterizing the “normal 
human microbiome” in the Human Microbiome Project (HMP) phase I and diseased h uman 
microbiome in the HMP phase II, no broad scale microbiome characterization effort has yet been 
made in the setting of cancer. Indeed, iHMP (or HMP2) prioritized multi -omic characterization of 
longitudinal samples from diseased individuals from three c ategories: pre -term birth, type 2 
diabetes mellitus, and inflammatory bowel disease. As recently outlined in the NIH Emerging 
Themes workshop on microbiome research (NIH, Bethesda, MD; August 15 – 18, 2018), the field 
has recognized the strong importance o f longitudinal sampling, high quality metadata collection, 
and simultaneous microbial and immunologic characterization.  
Novel methods being pioneered and perfected in microbiome research are likely to facilitate 
translational breakthroughs – these methods  allow (1) detailed taxonomic classification of 
microorganisms at the strain level, (2) metabolic characterization of the small molecules and 
proteins that a microbial community makes, (3) measurement of microbial genomic evolution in 
clinical time courses , and (4) culturing of previously fastidious organisms from the microbiome 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-7 for in vitro investigation and cultivation as potential therapeutic/adjuvant live bacterial clinical 
interventions. A well -curated, longitudinal biospecimen collection will facilita te validation of 
existing microbial biomarkers of disease and discovery of novel microbial biomarkers of disease 
that are generalizable. Particularly compelling is the fact that both preclinical and clinical studies 
support the role of the microbiome as a potentially modifiable biomarker of disease.33 In fact, the 
microbiome has already been causally associated with opportunistic infections such as C. difficile 
colitis, in which fecal microbiota transplantation is highly safe and effective.34 Furthermore, 
inflammatory diseases, such as IBD, are clearly modulated by the microbiome.35  
Given recent reports suggesting that alterations in the microbiome can impact the efficacy of 
immunologic therapies, there is a clear imperative that the strong and growing link between the 
microbiome and cancer outcomes be investigated.36,37 As the BMT CTN carries out a multitude of 
interventional clinical trials and has a strong track record for longitudinal sampling, high quality 
metadata collection, and immunologic characterization of patients post -HCT, the BMT CTN is 
ideally suited to lead  the first cancer -associated effort in this space.  
 
1.4.2 Protective Immunity  
The reconstitution and regain of function of a donor -derived immune system is of utmost 
importance for the recovery and long -term survival of patients after allogeneic HCT. 
Dysfunctio nal immune reconstitution after transplant is associated with several transplant -related 
complications and adverse transplant outcome. However, although the phenomenology of the 
many defects in protective immunity (both against infectious pathogens and aga inst leukemia 
relapse) is well -documented, the causative molecular mechanisms remain unknown.38 To address 
these questions, several groups, including investigators at FHCRC, MSKCC, and Stanford, have 
begun to perform detailed assessments of immunologic rec onstitution after allogeneic HCT 
including the application of new T Cell Receptor (TCR) and B Cell Receptor (BCR) deep -
sequencing technologies39-46 These technologies allow the investigation of the breadth and depth 
of post -transplant immune reconstitution  at a level of molecular detail not previously possible and 
hold the promise of deepening our understanding of the impact of infectious pathogens on global 
immune health and immune reconstitution. The widespread application of these technologies, and 
their intersection with detailed assessment of immune phenotype and function can provide novel 
insights about the state of immune health in transplant patients, and holds the promise of 
identifying patients in need of novel interventions to improve their post -transplant immune 
reconstitution.  
Accumulating evidence in recent years have indicated that the host microbiome has a tremendous 
influence on the generation and shaping of immune cell repertoire.47 Additionally, the microbiota 
affects the immune response ag ainst cancer. For example, there are studies demonstrating the 
association between intestinal microbiota and relapse after HCT32, or studies demonstrating that 
immune responses against cancer triggered by immune checkpoint inhibition are associated with 
the abundance of distinct members of intestinal microbiota.48,49 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 16, 2020  
Page 1-8 1.4.3 Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic 
Stem Cell Transplantation (Mi -Immune)  
Mi-Immune represents a  companion  study , where additional  key precision medicine and systems 
biology questions will be explored. The goal of this companion  study is several -fold:  First, it is to 
test the primary hypothesis that the engraftment stool microbiome diversity (determined by 16s 
rRNA sequencing analysis of the sample closest after, but within 14 days of neutrophil 
engraftment) predicts 1 -year non -relapse mortality  in patients undergoing reduced -intensity 
allogeneic HCT.  Second, it is to perform additional analyses on patient samples to answer key 
questions concerning: a)  the impact of the stool microbiome on transplant outcome as well as the 
impact of transplant on the microbiome and the associated downstream impact on patient health; 
and b) reconstitution of the T cell repertoire after transplant .  Third, it is to establish a cohort of 
biologic samples collected prospectively from patients treated on BMT CTN 1703  that will be a 
shared biospecimen resource for conducting future allogeneic HCT correlative studies.  The 
resulting dataset will become an additional resource generated by the trial  and will be made 
available to the biomedical community. Mi-Immune  is desi gned to link molecular data and 
biospecimens with high quality clinical phenotype and outcomes data to identify risk factors for 
development and severity of key complications after allogeneic HCT.  
 
1.5 Rationale for a Randomized Trial  
This multicenter Phase III clinical trial will evaluate 2 acute GVHD prophylaxis approaches for 
their efficac ies in improving the proportion of patients who do not develop severe acute GVHD, 
chronic GVHD that requires systemic therapy, disease progression, or relapse by one year post -
transplant.  Selection of the most promising therapy will be made based on the magni tude of 
difference in the primary endpoint.
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-1 CHAPTER 2  
2 STUDY DESIGN  
2.1 Study Overview  
The BMT CTN 1703  study is a Phase III randomized, open label, multicenter trial compar ing 
PTCy/Tac/MMF versus Tac/MTX for GVHD prophylaxis in patients with controlled maligna nt 
disease s receiving an allogeneic PBSC transplant after a RIC regimen. The primary endpoint is 
GRFS at 1 year.  
The study will collect stool, urine, and blood biospecimens, as well as detailed clinical data on 
infections and antibiotic exposures  in an attempt to understand the microbial and immune recovery 
predictors of HCT outcomes. Mi-Immune component of the study will form the correlative science 
arm of the BMT  CTN 1703 study (PROGRESS III), which will compare two acute GVHD 
prophylaxis regimens: Tac/MTX versus PTCy/Tac/MMF in the setting of RIC allogeneic PBSC  
transplantation.  
2.2 Hypothesis and Specific Objectives  
2.2.1 Primary Hypothesis   
BMT CTN 1703:  At 1 year, PTCy/ Tac/MMF GRFS will be 1 5% or greater compared to Tac/MTX 
GRFS.  
Mi-Immune study:  The engraftment stool microbiome diversity (determined within 14 days after 
neutrophil engraftment) predicts 1 -year non -relapse mortality.  
2.2.2 Study Objectives   
BMT CTN 1703:  The primary objective of the randomized trial is to compare 1 -year GRFS after 
HCT  between PTCy/Tac/MMF versus Tac/MTX. An event for this time to event outcome is 
defined as grade III -IV acute GVHD, chronic GVHD requiring systemic immune suppression , 
disease re lapse or progression, or death by any cause. Secondary objectives are grade II -IV and 
III-IV acute GVHD per the NIH Consensus Conference Criteria on Acute GVHD Grading by Day 
+180, rates of Minnesota standard and high risk acute GVHD by Day +180, rates of NIH mild, 
moderate, and severe chronic GVHD (defined by the NIH Consensus Conference Criteria)  at 1 
year, systemic immunosuppression -free survival at 1 year, hematologic recovery including 
neutrophil engraftment (first day of ANC greater th an or equal to 500 for 3 consecutive days), 
platelet engraftment (first day of sustained platelet greater than  or equal to  20,000, or greater than 
or equal to 50,000 with no platelet transfusion in preceding 7 days), lymphocyte recovery (first 
day of susta ined absolute lymphocyte count greater than  or equal to  1000), proportion of patients 
with full (at least 95% or more ) or mixed (5 .0-94.9%) total donor chimerism or graft rejection ( less 
than 5% total donor chimerism) at Day +100, disease relapse or progre ssion at 1 year, non -relapse 
mortality at 1 year, incidence of biopsy -confirmed PTLD at 1 year, incidence of infections at 1 
year, overall survival at 1 year, and patient -reported outcomes (PRO) at baseline, Day 100, Day 
180, 1 year.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-2 Mi-Immune study:  The goal of this protocol is to test the primary hypothesis that the engraftment 
stool microbiome diversity (determined by 16s rRNA sequencing analysis of the sample closest 
after, but within 14 days of neutrophil engraftment) predicts 1 -year non -relapse morta lity in 
patients undergoing reduced -intensity allogeneic HCT.   Mi-Immune secondary and exploratory 
objectives are addressed in Chapter 2 of Appendix J.  
2.3 Patient Eligibility  
2.3.1 Inclusion Criteria  
1. Age 18 .0 years or older  at the time of enrollment on Segment A   
2. Patients with acute leukemia or chronic myelogenous leukemia with no circulating blasts 
and with less than 5% blasts in the bone marrow   
3. Patients with myelodysplasia /chronic myelomonocytic leukemia  with no circulating blasts 
and with less than 10% blasts i n the bone marrow  (higher blast percentage allowed in MDS 
due to lack of differences in outcomes with <5% vs . 5-10% blasts in this disease)   
4. Patients with relapsed chronic lymphocytic leukemia /small  lymphocytic lymphoma  with 
chemosensitive disease at time of transplantation  
5. Patients with lymphoma  [follicular lymphoma, Hodgkin lymphoma, diffuse large B cell lymphoma, 
mantle cell lymphoma, peripheral T -cell lymphoma, angioimmunoblastic T -cell lymphoma and 
anaplastic large cell lymphoma ] with chemosensitive di sease at the time of transplantation   
6. Planned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)  
7. Patients must have a related or unrelated peripheral blood stem cell donor as follows:  
a. Sibling donor must be a 6/6 match for HLA -A an d -B at intermediate (or higher) 
resolution, and -DRB1 at high resolution using DNA -based typing and  must be 
willing to donate peripheral blood stem cells and meet institutional criteria for 
donation.  
b. Unrelated donor must be a 7/8 or 8/8 match at HLA -A, -B, -C and –DRB1 at high 
resolution using DNA -based typing. Unrelated donor must be willing to donate 
peripheral blood stem cells and meet NMDP criteria for donation . 
8. Cardiac function: Left ventricular ejection fraction at least  45% 
9. Estimated creatinine clearance acceptable per institutional guidelines  
10. Pulmonary function: DLCO  corrected for hemoglobin  at least  40% and FEV1 predicted 
at least  50%  
11. Liver function acceptable per institutional guidelines  
12. Karnofsky  Performance Score at least 60% 
13. Female patient s (unless postmenopausal for at least 1 year before the screening  visit, or 
surgically sterilized), agree to practice  two (2) effective methods of contraception at the 
same time, or agree to completely  abstain from heterosexual intercourse, from the time of 
signing the informed consent  through 12 months post -transplant .  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-3 14. Male patient s (even if surgically sterilized), of partners of women of childbearing potential 
must agree to  one of the following: practice effective barrier contraception , or abstain from 
heterosexual intercourse from the time of signing the informed consent  through 12 months 
post-transplant . 
15. Plans for the use  of post-transplant maintenance therapy must be disclosed upon 
enrollment and must be used irrespective of the outcome of the randomization .  
Please note  that THIS DOES NOT INCLUDE INVESTIGATIONAL AGENTS  and 
maintenance therapy with investigational treatment requires approval by the study chairs.    
16. Voluntary written  consent  obtained prior to the performance of any study -related 
procedure that is not a part of standard medical care, with the understanding that consent 
may be withdrawn by the patient at any time without prejudice to future medical care  
 
2.3.2 Exclusion Criteria  
1. Prior allogeneic transplant  
2. Active CNS involvement by malignant cells  
3. Patients with secondary acute myeloid leukemia arising from myeloprolifer ative disease, 
including CMML  
4. Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication 
and with progression or no clinical improvement) at time of enrollment.  
5. Presence of clinically significant fluid collection (ascites , pleural or pericardial effusion) 
that interferes with methotrexate clearance or makes methotrexate use contraindicated  
6. Patients seropositive for human immunodeficiency virus (HIV)  with detectable viral load. 
HIV+ patients with an undetectable viral load on antiviral therapy are eligible.  
7. Myocardial infarction within 6 months prior to enrollment or New York Heart Association 
(NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular 
arrhythmias, or electrocardiographic evid ence of acute ischemia.  
8. Female patients who are pregnant (as per institutional practice) or lactating  
9. Patients with a serious medical or psychiatric illness likely to interfere with participation 
in this clinical study  
10. Patients with prior malignancies except resected non -melanoma skin cancer or treated 
cervical carcinoma in situ.  Cancer treated with curative intent ≥ 5 years previously will be 
allowed.  Cancer treated with curative intent < 5 years previously must be revi ewed and 
approved by the Protocol Officer or Chairs.  
11. Planned use of ATG or alemtuzumab in conditioning regimen  
 
2.4 Treatment Plans  
It is recommended that adjusted ideal body weight be used when calculating conditioning 
regimen chemotherapy doses.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-4  
Ideal Body Weight (IBW) Formulas:  
 
Males IBW = 50 kg + 2.3 kg/inch over 5 feet  
 
Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet  
 
Adjusted Ideal Body Weight Formula:  
 
AIBW = IBW + [(0.25) x (ABW * - IBW)]  
 
2.4.1 Conditioning Regimens  
Eligible patients will receive a red uced intensity or nonmyeloablative conditioning regimen 
according to Table 2 .4A. Other regimens deemed to be RIC by the transplant center and not 
included in Table 2 .4A should be submitted to the Protocol Coordinator for consideration by the 
Protocol Chairs and/or O fficer . 
*ABW: Actual Body Weight   
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-5 Table  2.4A: Conditioning Regimens1 
Reduced Intensity Conditioning  Nonmyeloablative Conditioning  
Fludarabine/Busulfan (Flu/Bu)  
• Fludarabine (120 -180 mg/m2) 
• Busulfan ( less than or equal to 8 
mg/kg PO or 6.4 mg/kg IV)   Fludarabine/Cyclophosphamide (Flu/Cy)  
• Fludarabine (90 -120 mg/m2) 
• Cyclophosphamide (120 mg/kg or 2250 
mg/m2) 
Fludarabine/Melphalan ( Flu/Mel)  
• Fludarabine (120 -180 mg/m2) 
• Melphalan (less than or equal to 150 
mg/m2) Fludarabine /Total Body Irradiation 
(Flu/TBI)  
• Fludarabine (90 mg/m2) 
• TBI (200 cGy)  
 Fludarabine/ Cyclophosphamide/TBI 
(Flu/Cy/TBI)  
• Fludarabine (150 mg/m2) 
• TBI (200 cGy)  
• Cyclophosphamide (29 -50 mg/kg)  
1Addition of antithymocyte  globulin or alemtuzumab is not allowed.  
 
Fludarabine and busulfan (Flu/Bu)  
The recommended Flu/Bu regimen is the following:  
• Days -6 to -2: Flu (30 mg/m2/day, total dose of 150 mg/m2) 
Busulfan Options  
Busulfan without PK - Days -5 to -4: Busulfan (4 mg/kg/day PO or 3.2 mg/kg/day IV or 
130 mg/m2/day IV; total dose of 8 mg/kg PO or 6.4 mg/kg IV or 260 mg/m2 IV 
respectively)  
Busulfan with PK – target doses to area under the curve of 4000μMol/min (course AUC 
16000μMol/min) or less is allowed.  
The sequence  of fludarabine and busulfan administration  may follow institutional 
practice .  
 
Fludarabine and melphalan (Flu/Mel ) 
The recommended Flu/Mel regimen is the following:  
• Days -5 to -2: Flu (30 mg/m2/day, total dose of 120 mg/m2) 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-6 • Day -1: Mel (140 mg/m2) 
The se quence of fludarabine and melphalan administration will be done according to institutional 
standards as long as the prescribed doses are the same as the recommended regimen above.  
Dividing the dose of melphalan into two days is allowed.  
Fludarabine and cyclophosphamide (Flu/Cy)  
The recommended Flu/Cy regimen is the following:  
• Days -5 to -3: Flu (30 mg/m2/day, total dose of 90 mg/m2) 
• Days -4 to -2: Cyclophosphamide (750 mg/m2/day, total dose of 2250 mg/m2) 
Alternatively:  
• Days -3 to -2: Cyclophosphamide (60 mg/kg/day, total dose of 120 mg/kg)  
The sequence of fludarabine and cyclophosphamide administration will be done according to 
institutional standards as long as the prescribed doses are the same as the recommended regimen 
above.  Hydrat ion and Mesna may be administered per institutional guidelines. Addition of 
rituximab conditioning in patients with lymphoproliferative disease is allowed.  Dose and intervals 
of rituximab conditioning can be determined according to institutional guidelines . However, 
rituximab use after stem cell infusion is not permitted.  
 
Fludarabine and total body irradiation (Flu/TBI)  
The recommended Flu/TBI regimen is the following:  
• Days -5 to -3: Flu (30 mg/m2/day, total dose of 90 mg/m2) 
• Day -1 or 0: TBI 200 cGY (pr e-stem cell infusion)  
 
Fludarabine, total body irradiation and cyclophosphamide (Flu/Cy/TBI)  
The recommend Flu/Cy/TBI regimen is the following:  
• Days -6 to -5: Cy (14.5 mg/kg/day, total dose of 29 mg/kg , or single dose 50 mg/kg on day 
-6 [Minnesota regimen] ) 
• Days -6 to -2: Flu (30 mg/m2/day, total dose of 150 mg/m2) 
• Day -1: TBI 200 cGY  
 
Hydration and Mesna may be administered per institutional standards.   Fludarabine can be dose 
adjusted per institutional standards.   
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-7 2.4.2 Hematopoietic Stem Cell Transplantation  (HCT ) 
Mobilized PBSC is the only allowed graft source for patients enrolled in this clinical trial.  
Donors will undergo G -CSF and/or plerixafor mobilization accordin g to local institutional and 
donor center practices.  PBSC will be collected by apheresis according to local institutional 
guidelines.  Plasma and red cell depletion are allowed for volume reduction or ABO incompatibility 
but any other form of graft manipula tion (including ex -vivo T cell depletion) is not permitted.  
The target stem cell dose is a minimum of 2 x 106/kg and a maximum 10 x 106/kg (actual body 
weight) CD34+ cells. The maximum CD34+ cell dose is 10 x 106/kg.   
Up to two leukapheresis procedures may be performed to obtain the minimum CD34+ cell target.  
If, after two leukapheresis procedures, fewer than 2 x 106/kg CD34+ cells have been collected, 
transplant cen ters will have the discretion to continue PBSC cell harvesting or to proceed to bone 
marrow harvesting to obtain sufficient cells.  A third leukapheresis procedure is discouraged. If 
bone marrow harvesting is needed in order to meet the desired cell dose, t he transplant center needs 
to notify the Protocol Coordinator, in addition to the Protocol Chairs and/or Officer.   
If more than 10 x 106/kg CD34+ stem cells are collected, the excess will either be discarded or 
cryopreserved for future use, but will not be  administered to the patient.   PBSC will be 
administered on Day 0 to all patients according to individual institutional guidelines after 
appropriate processing and quantification has been performed by the local laboratory. If two 
leukapheresis procedures a re performed to obtain the minimum CD34+ cell dose target, the two 
products must be combined and infused together on one day. Stem cells are administered through 
an indwelling central venous catheter.  
2.4.3 Tacrolimus/Methotrexate  
Tacrolimus will be given per i nstitutional practices, orally at a dose of 0.05 -0.06 mg/kg /day or 
intravenously at a dose of 0.0 2-0.03 mg/kg /day starting  on Day –3. The dose of tacrolimus may be 
rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood 
levels per institutional guidelines with a suggested range of 5 -15. If patients are on medications 
which alter the metabolism of tacrolimus (e.g.  concurrent CYP3A4 inhibitors ), the initial starting 
dose and subsequent  doses should be altered as per institutional practices . Tacrolimus taper can be 
initiated at a minimum of 90 days post HCT  if there is no evidence of active GVHD.  The rate of 
tapering will be done according institutional practices and patients should be off tacrolimus by 
Day 180 post HCT  if there is no evidence of active GVHD.  
Dose reductions should be made if toxicity is present or whole blood levels are above the 
recommended range, in the absence of toxicity.  Patients with severe intolerance of tacrolimus may 
be placed on cyclosporine (trough level of 200 -400 ng/mL) or sirolimus (trough level of 5 -10 
ng/mL).  
Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1 and 10 mg/m2 IV 
bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion.  Methotrexate should be 
dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per 
institutional guidelines.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-8  
2.4.4 Tacrolimus/Mycophenolate Mofetil/Cyclophosphamide  
Tacrolimus  
Tacrolimus will be given per institutional practices, orally at a dose of 0.05 -0.06 mg/kg /day or 
intravenously at a dose of 0.0 2-0.03 mg/kg /day starting Day +5. Starting tacrolimus dose can be 
modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) 
according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then 
should be checked  weekly thereafter, and the dose adjusted accordingly to maintain a suggested 
level of 5-15 ng/mL.  Tacrolimus taper can be initiated at a minimum of 90 days post HCT  if there 
is no evidence of active  GVHD.   The rate of tapering will be done according to institutional 
practices  but patients should be off tacrolimus by Day 180 post HCT  if there is no evidence of 
active GVHD.  
Dose reductions should be made if toxicity is present or whole blood levels are above the 
recommended range, in the absence of toxicity.  Patients with severe intolerance of tacrolimus may 
be placed on cyclosporine (trough level of 200 -400 ng/mL) or sirolimus (trough level of 5 -10 
ng/mL).  
Mycophenolate mofetil (MMF)  
MMF will be given at a dose of 15 mg/kg /dose  TID (based upon actual body weight) with the 
maximum total daily dose not to exceed 3 grams (1g TID, IV or PO).  MMF prophylaxis will start 
Day +5 and discontinue after the last dose on Day +35 or may be continued if active GVHD is 
present.  
Cyclophosphami de 
Hydration prior to cyclophosphamide may be given according to institutional standards.  A 
recommended  approach is as follows:  Patients are instructed to increase fluids overnight before 
cyclophosphamide administration.  Hydration with normal saline at 3 m l/kg/hr IV will be started 2 
hours prior to cyclophosphamide, then the rate will be reduced to 2 ml/kg/hr for 1 hour pre -
cyclophosphamide and continued at 2 ml/kg/hr for 8 hours post -cyclophosphamide.  
Mesna will be given in divided doses IV 30 min pre - and at 3, 6, and 8 hours post -
cyclophosphamide or administered per institutional standards.  Mesna dose will be based on the 
cyclophosphamide dose being given.  The total daily dose of Mesna is equal to 80 %-100% of the 
total daily dose of cyclophosphamide.   
Cyclophosphamide [50 mg/kg IBW; if ABW < IBW, use ABW ] will be given on Day +3 (between 
60 and 72 hours after the start of the PBSC infusion) and on Day +4 post -transplant (approximately 
24 hours after Day +3 cyclophosphamide).  Cyclophosphamide will be given as an IV infusion over 
1-2 hours (depending on volume).  
It is crucial that no systemic immunosuppressive agents , such as corticosteroids,  are given from 
day 0  until 24 hours  after the completion of the post -transplant cyclophosphamide (Day +5).  This 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-9 rule applies only to the post -transplant cyclophosphamide arm of the study This includes 
corticosteroids as anti -emetics , however, replacement doses of chronic glucocorticoids for 
adrenal insufficiency are allowed . 
2.5 Supportive Care  
All supportive care will b e given in keeping with local institutional practice.  Supportive care will 
be administered in a similar fashion to patient s randomized to both arms of the study.  
2.5.1 Growth Factors  
G-CSF may be given per institutional guidelines.  
2.5.2 Blood Products  
Transfusion th resholds for blood product support will be consistent with standard institutional 
guidelines.  All blood products will be irradiated.  
2.5.3 Prophylaxis Against Infections  
Patients will receive infection prophylaxis according to institutional guidelines. Infection  
prophylaxis will include, but is not limited to, agents or strategies (e.g., PCR screening and 
preemptive therapy) to reduce the risk of bacterial, herpes simplex, CMV, HHV -6, EBV, 
Pneumocystis jiroveci i, and fungal infections:  
• Antifungal therapy: Prophyl axis with fluconazole or other antifungal agents  can be given 
as per local institutional guidelines.   
o Flucon azole, voriconazole and other azoles  (CYP3A4 inhibitors)  are expected to 
increase serum tacrolimus levels, therefore, dosages of tacrolimus should be 
adjusted accordingly.  
• CMV: CMV monitoring will be done according to institutional guidelines. It is 
recommended that weekly assessment for CMV be done through Da y 60 post -transplant. 
Use of letermovir is allowed.  Any reactivation and/or CMV disease will be captured in this 
study. An Infection form must be submitted in Advantage eClinical.   
 
2.5.4 Intravenous Immune Globulin (IVIG)  
IVIG administration will be according to local institutional standard practice.  
2.6 Participant Risks  
2.6.1 Therapy Toxicities  
All toxicities will be graded using the Common Terminology Criteria for Adverse Events 
(CTCAE) Version 5.0.  
2.6.2 Tacrolimus  
Tacrolimus side effects include:  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-10 • Cardiovascular:  pericardial effusion, hypertension  (which may cause arrhythmia, angina, 
myocardial infarction)  
• Cutaneous: itching, rash  
• Endocrine and metabolic: hyperglycemia, hypomagnesemia, hypokalemia, hyperkalemia, 
hypophosphatemia, hyperlipidemia  
• Gastrointestinal: constipation, diarrhea, nausea, vomiting , anorexia, bowel perforation, 
dyspepsia  
• General: fatigue  
• Hematologic: anemia, thrombocytopenia, leukopenia, thrombotic microangiopathy  
• Hepatic: liver dysfunction  
• Neurologic: paresthesia, headache, tremor, encephalop athy/posterior reversible 
encephalopathy syndrome (PRES), dizziness, insomnia, confusion, altered mental status, 
seizure, blindness  
• Pulmonary: pleural effusion, dyspnea  
• Renal: renal impairment which may require dialysis, peripheral edema  
• Miscellaneous: infection, post-transplant lymphoproliferative disorders , allergic reaction, 
secondary malignancy   
 
2.6.3 Methotrexate  
Methotrexate side effects include:  
• Cardiac and vascular: thrombosis  
• Cutaneous: photosensitivity, rash, alopecia, erythema multiforme  
• Gastroinstestinal: nausea, vomiting, diarrhea , pain, anorexia, ulcers, gastrointestinal 
bleeding, mucositis  
• General: fatigue  
• Hematologic: anemia, thrombocytopenia, leukopenia  
• Pulmonary: pulmonary fibrosis  
• Renal: nephrotoxicity  
• Miscellaneous: secondary mali gnancy, infection  
 
2.6.4 Mycophenolate mofetil (MMF)  
MMF side effects include:  
• Cardiac and vascular: hypertension, hypotension, tachycardia, edema  
• Cutaneous: rash  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-11 • Endocrine and metabolic: hypocalcemia, hypokalemia, hyperuricemia, hyperkalemia, 
hypomagnesemia  
• Gastrointestinal: nausea, vomiting, dyspepsia, abdominal pain, diarrhea  
• Hematologic: leukopenia,  thrombocytopenia, anemia  
• Neurologic: headache, tremors, insomnia, dizziness, progressive multifocal 
leukoencephalopathy (PML)  
• Pulmonary: dyspnea , cough, interstitial lung disease  
• Miscellaneous: change in vision, infection, secondary malignancy, arthralgia, myalgia  
 
2.6.5 Cyclophosphamide  
Cyclophosphamide side effects include:  
• Card iac and vascular: heart failure (which can result in edema, effusion, dyspnea)  
• Cutaneous: alopecia, rash, hyperpigmentation of skin and nails  
• Gastrointestinal: nausea, vomiting, anorexia, mucositi s, stomatitis, abdominal pain, 
diarrhea  
• General: lethargy  
• Hematologic: leukopenia, thrombocytopenia, anemia  
• Pulmonary: pulmonary fibrosis  
• Endocrine: amenorrhea, gonadal function impairment, sterility, syndrome of inappropriate 
antidiuretic hormone secretio n (SIADH) – with associated cerebral edema  
• Genitourinary: hemorrhagic cystitis  
• Miscellaneous: infection, allergic reaction including anaphylaxis, secondary malignancy  
 
2.6.6 Busulfan  
Busulfan side effects include:  
• Cardiac: arrhythmia, edema, hypertension, tachy cardia, pericardial effusion, heart failure, 
hypotension  
• Cutaneous: rash , hyperpigmentation, pruritis  
• Gastrointestinal: constipation, diarrhea, dyspepsia, nausea, vomiting, anorexia, mucositis, 
dysphagia  
• General: chills, fever, pain, fatigue  
• Genitourinary: gonadal function impairment, menopause  
• Endocrine: hypomagnesemia, hyperglycemia, hypokalemia, hypocalcemia  
• Hematologic: anemia, thrombocytopenia, leukopenia  
• Hepatic: hepatic impairment, hepatic sinusoidal obstruction syndrome  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-12 • Neurologic: diz ziness, headache, insomnia, seizure , anxiety, depression  
• Pulmonary: cough, nasal congestion, hemoptysis, interstitial pulmonary fibrosis  
• Renal:  hematuria, renal impairment  
• Miscellaneous: infection, allergic reaction including anaphylaxis, visual impairment  
2.6.7 Fludarabine  
Fludarabine side effects include:  
• Gastrointestinal: vomiting, anorexia, nausea , mucositis  
• General: fatigue, fever, chills  
• Hematologic: anemia, thrombocytopenia , neutropenia  
• Hepatic: increased liver function tests   
• Neurologic: paresthesia, conf usion , seizure, agitation, visual disturbances, pain  
• Pulmonary: cough, shortness of breath  
• Renal: renal impairment , hematuria  
• Miscellaneous: infection, general organ damage  
2.6.8 Melphalan  
Melphalan side effects include:  
• Cardiac and vascular: edema, heart failure , vasculitis  
• Gastrointestinal: mucositis, nausea, vomiting, diarrhea  
• General: fatigue  
• Hematologic: anemia, thrombocytopenia, neutropenia   
• Hepatic: abnormal liver function tests, hepatitis  
• Pulmonary: shortness of breath, pulmonary fibrosis  
• Renal: ren al impairment  
• Miscellaneous: allergic reaction including anaphylaxis, secondary malignancy  
2.6.9 Total Body Irradiation (TBI)  
Low Dose TBI side effects include:  
• Cutaneous: erythema, hyperpigmentation, alopecia  
• Gastrointestinal: nausea, vomiting, diarrhea, parot itis, mucositis, abdominal cramping  
• General: fever, fatigue  
• Genitourinary: gonadal impairment  
• Hepatic: hepatic sinusoidal obstruction syndrome  
• Hematologic: myelosuppression, anemia, thrombocytopenia  
• Pulmonary: interstitial pneumoniti s 
• Renal: nephropathy  
• Miscellaneous: infection, short stature, vertebral deformities, cataracts, secondary 
malignancy, hormonal impairment  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 2-13 2.7 Study Drug Supply  
Tacrolimus, methotrexate, cyclophosphamide  and mycophenolate mofetil are commercially 
available agents and will not be provided by the study.  Please administer as described in  
Section 2.4.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 3-1 CHAPTER 3  
3 STUDY ENDPOINTS  
3.1 Primary Endpoint  
BMT CTN 1703 : The primary endpoint is GVHD/relapse or progression -free survival (GRFS).  
An event for this time to event outcome is defined as grade III-IV acute GVHD, chronic GVHD  
requiring systemic immune suppression , disease relapse or progression, or death by any cause.   
Use of systemic immunosuppressive therapy for treatment of chronic GVHD is at the discretion 
of the treating physicians.  The event of interest is the development of chronic GVHD severe 
enough to warrant any additional systemic treatment(s).  Also, continuation of study -mandated 
GVHD prophylaxis beyond Day 180 in the presence of chronic GVHD will also be considered  an 
event with time to event determined as date of chronic GVHD onset.   
Mi-Immune:  The primary endpoint is non -relapse mortality within one year.  This endpoint is 
defined according to the BMT CTN 1703 protocol.  This primary endpoint will be associated wi th 
the engraftment stool microbiome diversity (grouped by tertiles) for the primary  analysis of this 
study .  Mi -Immune secondary endpoints are addressed in Chapter 3 of Appendix J.  
3.2 Secondary Endpoints  
3.2.1 Acute GVHD  
Cumulative incidences of grade II -IV and III -IV acute GVHD will be determined.  Acute GVHD 
will be graded according to the BMT CTN Technical MOP  (see Appendix G) . The time of onset 
of acute grades II -IV and III -IV acute GVHD will be recorded, as well as the maximum grade 
achieved.  Within the acute GV HD endpoint, the proportion of patients with visceral involvement 
(liver or gut) will be described.  
Cumulative incidences of Minnesota standard and high risk acute GVHD will also be determined.  
3.2.2 Chronic GVHD  
The cumulative incidence of chronic GVHD will b e determined.  Data will be collected directly 
from providers and chart review as defined by  the NIH Consensus Conference  Criteria . Eight 
organs will be scored on a 0 -3 scale to reflect degree of chronic GVHD involvement.  Liver and 
pulmonary function test r esults, and use of systemic therapy for treatment of chronic GVHD will 
also be recorded.  These data will allow calculation of the NIH global severity scores of mild, 
moderate and severe chronic GVHD, which has been associated with transplant related mortal ity 
and overall survival.  Assessment of chronic GVHD will occur up to 1 year post -transplant .  
3.2.3 Systemic Immunosuppression -free Survival  
Patients who are alive, relapse -free, and do not need ongoing immune suppression to control 
GVHD at one year post -transplant  are considered successes for this endpoint.  Immune suppression 
is defined as any systemic agents used to control or suppress GVHD.  Corticosteroid doses greater 
than 10 mg will be considered active systemic immune suppression treatment.  Patients who 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 3-2 discontinued immune suppression within  15 days or less prior to the 1 -year time point will be 
considered to be on immune suppression for t his endpoint.  
3.2.4 Hematologic Recovery  
Hematologic recovery will be assessed according to neutrophil and platelet counts recovery after 
transplant . Neutrophil recovery is defined as achieving an absolute neutrophil count (ANC)  
greater than or equal to  500/mm3 for three consecutive measurements on three different days.  The 
first of the three days will be designated the day of neutrophil recovery.  The competing event is 
death without neutrophil recovery.  For patients who never drop ANC below 500/mm3, the date o f 
neutrophil recovery will be Day +1 post -transplant .  
Platelet recovery is defined by two different metrics: the first day of a sustained platelet count 
greater than  or equal to  20,000/mm3 or greater than or equal to 50,000/mm3 with no platelet 
transfusio ns in the preceding seven days.  The first day of sustained platelet count above these 
thresholds will be designated the day of platelet engraftment.  For patients who never drop their 
platelet count below 20,000/mm3 or 50,000/mm3, the date of platelet recovery will be Day +1 post 
HCT.  
Lymphocyte recovery will be defined as the first day of sustained absolute lymphocyte count 
greater than  or equal to 1000/mm3. 
3.2.5 Donor Cell Engraftment  
Donor cell engraftment will be assessed with donor/recipient chimerism studies.  Chimerism may 
be evaluated in bone marrow, whole  unfractionated  blood or blood cell fractions, including CD3 
and CD33 or CD15 fraction.  For the purpose of this protocol, mixed chimerism is defined as the 
presence of donor  cells, as a proportion of total cells to be less than  95% but at least  5% in the 
bone marrow or peripheral blood.  Full donor chimerism is defined as greater than or equal to 95% 
of donor cells. Mixed and full chimerism will be evidence of donor cell engra ftment.  Donor cells 
of less than  5% will be considered as graft rejection.  The proportion of patients with each level of 
chimerism described above will be described as part of this outcome.  For sorted blood cell 
fractions, CD3+ donor cell chimerism will be  used to define the donor/recipient chimerism status.  
3.2.6 Disease Relapse o r Progression  
Relapse is defined by either morphological or cytogenetic evidence of acute leukemia or MDS 
consistent with pre -transplant features, or radiologic evidence of lymphoma, d ocumented or not 
by biopsy.  Progression of disease applies to patients with lymphoproliferative diseases (lymphoma 
or chronic lymphocytic leukemia) not in remission prior to transplantation.  The event is defined 
as increase in size of prior sites of diseas e or evidence of new sites of disease, documented or not 
by biopsy.  
Acute leukemia and MDS  – Relapse will be diagnosed when there is:  
- Reappearance of leukemia blast cells in the peripheral blood; or,  
- Greater than 5% blasts in the bone marrow, not attribut able to another cause (e.g. bone 
marrow regeneration)  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 3-3 - The appearance of previous or new dysplastic changes (MDS specific) within the bone 
marrow with or without falling donor chimerism; or  
- The development of extramedullary leukemia or leukemic cells in the cerebral spinal fluid 
or 
- The reappearance of cytogenetic abnormalities present prior to transplantation  
 
Lymphoproliferative Diseases  – Relapse or progression will be diagnosed when there is:  
- Appearance of any new lesion more than 1.5 cm in any axis du ring or at the end of therapy, 
even if other lesions are decreasing in size.  Increased FDG uptake in a previously 
unaffected site will only be considered relapsed or progressive disease after confirmation 
with other modalities. In patients with no prior hi story of pulmonary lymphoma, new lung 
nodules identified by CT are mostly benign.  Thus, a therapeutic decision should not be 
made solely on the basis of the PET without histologic confirmation.  
- At least a 50% increase from nadir in the sum of the product d iameters of any previously 
involved nodes, or in a single involved node, or the size of other lesions (e.g., splenic or 
hepatic nodules).  To be considered progressive disease, a lymph node with a diameter of 
the short axis of less than 1.0 cm must increase  by at least 50% or more and to a size of 1.5 
x 1.5 cm or more than 1.5 cm in the long axis.  
Lesions should be PET positive if observed in a typical FDG -avid lymphoma or the lesion 
was PET positive before therapy unless the lesion is too small to be detec ted with current 
PET systems (less than 1.5 cm in its long axis by CT).  
- In addition to the criteria above, patients with CLL who present in complete remission prior 
to transplantation may fulfill the relapse definition if there is reappearance of circulating 
malignant cells that are phenotypically characteristic of CLL.  
 
Institution of any therapy to treat persistent, progressive or relapsed disease, including the 
withdrawal of immunosuppressive therapy or donor lymphocyte infusion, will be considered 
evidence of relapse/progression regardless of whether the criteria described  above were met.  
3.2.7 Transplant -related Mortality  
The cumulative incidence of TRM will be estimated at Days 100, 180  and 1 year after HCT.  An 
event for this endpoint is death without evidence of disease progression or recurrence. Disease 
progression or recurrence will be considered competing events.  
3.2.8 Toxicity  
All grade  3-5 toxicities according to CTCAE, version 5.0 will be tabulated for each intervention 
arm. The proportion of patients developing at least a grade 3  or more  AE across interve ntion arms 
will be compared.  
3.2.9 Infections  
The incidence of definite and probable viral, fungal and bacterial infections will be tabulated for 
each intervention arm.  The cumulative incidence of treated CMV reactivation in the first 100 days 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 3-4 post-transplant will be described.  All Grade 2 and 3 infections will be reported according to the 
BMT CTN Technical MOP up to 1 year post transplant .  
3.2.10  Disease -Free Survival  
Disease -free survival is the time from date of transplant to death or relapse/progression, whichever 
comes first.  The event for this endpoint is relapse/progression or death.  Patients alive and disease 
free will be censored at last follow -up.  
3.2.11  Overall Survival  
Overall survival is defined as the time interval between date of transplant and death from any 
cause.  The event for this endpoint is death from any cause. Surviving patients will be censored at 
last follow -up.  
3.2.12  PTLD  
The incidence of post -transplant lymphoproliferative disease (PTLD) will be measured at one year 
post-transplant . 
3.2.13  Patient -Reported Outco mes (PRO)  
PRO will be measured at Baseline and then at Day 100, Day 180 and 1 year post -transplant  using 
the Lee Chronic GVHD Symptom Scale , Hemorrhagic Cystiti s symptom questions, and selected 
PROMIS subscales  for gastrointestinal symptoms, physical function and satisfaction with 
participation in social roles . The instruments will be scored according to the recommendations of 
the developers.  PRO data will be collected electronically, or on paper vial mail if re quested by the 
patient.  Whether collected electronically or on paper, PRO data will be entered in the CIBMTR’s 
ePRO system.  The PRO instruments will only be offered to English and Spanish speaking patients.  
3.3 Endpoint Review Process  
Upon completion of par ticipant follow -up, an Endpoint Review Committee (ERC) will conduct an 
independent review of site -reported data on key study endpoints to determine the endpoint data to 
be presented in the primary manuscript and final analysis.  This Committee will consist  of members 
of the protocol team, including the Protocol Chairs, Protocol Officer, Operational Statistician, and 
Protocol Coordinator.  Each participant’s data will be reviewed by ERC clinicians.  The 
adjudicated endpoint data for each participant will be determined by consensus of their reviewers.   
The ERC will employ a risk -based strategy to the data review.  First, a random sample of 20% of 
the total study population will be chosen.  The key endpoints will be determined in two ways: 
using ERC adjudicati ons and using the site -reported data.  The concordance between the ERC 
adjudicated and site -reported endpoints will be computed.  If the concordance is 90% or above, 
the ERC will end and site -reported endpoints will be used for all statistical analyses.  I f the 
concordance falls below 90%, a second random subset of 20% of study participants will be drawn 
from the unadjudicated participants.  Then, the concordance between ERC adjudicated and site -
reported endpoints in the combined first and second subsets wi ll be computed.  If the concordance 
is 90% or above, the ERC will end and site -reported data will be used for all statistical analyses.  
Otherwise, all remaining, unadjudicated participants will undergo review and the ERC adjudicated 
endpoints for the enti re study population will be used in all statistical analyses.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 3-5 Data will be obtained from the relevant case report forms and  source documents and will be 
provided to reviewers in a blinded manner with respect to treatment assignment, treat ment center, 
and participant identifier.  These data will be kept confidential and will  not be discussed outside  
the Committee or presented in a public forum.
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-1 CHAPTER 4  
4 PATIENT ENROLLMENT AND EVALUATION  
4.1 Approaching Patients, Eligibility Screening and Obtaining Consent  
Patient s will be approached for this study after the decision to proceed with transplantation is 
made and a n HLA -matched PBSC donor is identified. Patients willing to participate in the trial 
will sign an NMDP IRB -approved consent form. Transplant physicians will evaluate the patient 
eligibility for randomization onto this study (see Section 2.2). Eligibility criteria will be verified,  
and ineligible patients will not be randomized,  and no further follow -up will be  obtained . 
Transplant center personnel will record the documentation of patient consent  and register the 
patient in Segment 0 of the study  in Advantage eClinical (Electronic Data Capture, an Internet -
based data entry system) .  Patients also need to sign the CIBMTR “Protocol for a Research 
Database for Hematopoietic Cell Transplantation and Marrow Toxic Injuries” consent form 
because future laboratory correlative studies using any remaining stored res earch samples will 
require linking with clinical data collected CIBMTR.     In cases where the HLA -matched donor 
is a related donor, t he patient’s donor who is 18 years of age or older should be approached to 
provide consent for the Mi -Immune study samples. Unrelated donors will be approached for 
consent for the Mi -Immune study by the NMDP.  
4.2 Transplant Protocol Registration  
Before randomization occurs, the transplant center must state through Advantage eClini cal 
which conditioning regimen and which maintenance regimen (if any) will be used for the 
enrolled patient . Such a registration step will avoid potential biases that preferential use of a 
certain regimen on one treatment arm could confer to the study. At this stage, the transplant 
center will also verify that the patient is still a candidate for transplantation, and eligible for the  
trial. The transplant center will also record the donor’s willingness to participate in  the Mi-
Immune  study .  At this point the patient is enrolled into Segment A of the study.   
At the time of enrollment in Segment A, transplant center personnel will securely email or fax 
patient contact information to the CIBMTR Survey Research Group for purpose of contacting 
patients for PRO administration.  
4.3 Randomization  
Once the patient  is deemed eligible and has given written informed consent, and the transplant 
center has confirmed patient eligibility and registered the patient’s conditioning and 
maintenance regimen, randomiz ation occurs. Patients should not be randomized more than 14 
days prior to  the planned initiation of conditioning. If initiation of conditioning has not started 
within 14 days of randomization , the Protocol Coordinator and P rotocol Chairs  and Officer  must  
be notified.  Refer to section 4.6.1 Patient Assessments -pre-transplant evaluations.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-2 4.4 Treatment Scheduling  
Treatment should be initiated as soon as possible after randomization. This will prevent patient  
attrition prior to transplant for re asons such as disease progression. Consequently, all treatments 
related to the transplant should be scheduled prior  to randomization. This includes planning an 
admission date and ensuring that the PBSC donor can be mobilized and undergo apheresis in a 
coordinated fashion with the planned transplant.  
4.5 Patient Evaluation  
The patient pre -transplant evaluation must be completed within 60  days of randomization  
(exceptions noted in the Study Calendar). See section 4.6.1 Patient Assessments -pre-transplant 
evaluatio ns. This step is necessary because patient organ function, infection status, and status of 
malignancy may vary over time. This evaluation will protect patients with a new 
contraindication to transplant from initiating transplant therapy at an unsafe time.  
4.6 Study Monitoring  
The follow -up schedule for scheduled study visits is outlined in Table 4. 6A. A detailed 
description of each of the forms and the procedures required for forms completion and 
submission can be found in the Data Management Handbook and User’s  Guide.  
TABLE 4.6A: FOLLOW -UP SCHEDULE  
Study Visit  Target Day Post -Transplant  
Day of Transplant  Day 0 * 
1 week  7  3 days  
2 week s 14  3 days  
3 week s 21  3 days  
4 week s 28  3 days  
5 week s 35  3 days  
6 week s 42  3 days  
7 week s 49  3 days  
8 week s 56  3 days  
9 week s 63  3 days  
10 week s 70  3 days  
11 week s 77  3 days  
12 week s 84  3 days  
14 week s 98  7 days  
6 month s 180  28 days  
9 month s 270  28 days 
12 month s 365  28 days  
24 month s 730  60 days 
*If infusion  occurs over 2 days, the day of transplant should be recorded as the day 
the first infusion occurred.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-3 4.6.1 Patient Assessments  
Table 4 .6B summarizes patient clinical assessments over the course of the study.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-4 TABLE 4.6B: PATIENT AND DONOR CLINICAL ASSESSMENTS  
 
Pre-
Conditioning  Pre-
infusion  0 7 14 21 28 35 42 49 56 63 70 77 84 98 180 270 365 730 
History, physical exam, weight 
and height10 X X  X X X X X X X X X X X X X X X X  
Karnofsky  performance status 
(see Appendix D) X               X X X X  
HCT -Specific Comorbidity 
Index score (see Appendix E) X                    
Disease Risk Index (see 
Appendix F) X                    
Donor and recipient HLA 
typing  X                    
CBC1, differential, platelet 
count, and blood chemistries2 X X  X X X X X X X X X X X X X X X X X 
Infectious disease titers3 X                    
EKG and LVEF  X                    
DLCO corr and FEV1 predicted   X                    
Disease evaluation4 X               X   X  
Chest x -ray or chest CT  X                    
Pregnancy test5 X                    
GVHD assessments6    X X X X X X X X X X X X X X X X  
Toxicity assessments7       X    X     X X X X  
Infection assessments  X  X  X  X  X  X  X  X X X X X  
Chimerism8 X      X         X     
Patient Mi -Immune research  
samples (see Appendix J)9 X9 X X X X X X X X X X X X X X X X X X X 
Related donor CBC11  X                   
Related donor Mi -Immune 
research samples  
(see Appendix J)   
X                   
Patient Reported Outcomes 
(see Appendix H) X               X X  X  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-5 1CBC with differential performed three times weekly from Day 0 until ANC at least  500/mcL or greater  for three days and platelet count at least 20,000/mcL or 
greater after nadir, while hospitalized. CBC then performed weekly through Day 84 post-transplant, t hen at Days 98, 180, 270 , 365 and 730 post-transplant .  A 
CBC needs to be collected at the same time as the scheduled Mi -Immune research samples and reporte d in Advantage eClinical.  
2Blood chemistries include: serum creatinine, albumin, bilirubin, alkaline phosphatase, AST and ALT. Blood chemistries performed twice weekly until hospital 
discharge. Blood chemistries performed weekly after hospital discharge u ntil Day 84 post-transplant, then at Days 98, 180, 270 and 365 post -transplant.  
3Infectious disease titers should be performed per institutional guidelines and may include: CMV, Hepatitis panel (HepA Ab, He pB SAb, HepB SAg, HepB Core 
Ab, HepC Ab), herpes s implex virus, syphilis, HIV and HTLV I/II antibody, and varicella zoster.  
4Evaluation of disease: (A) For acute leukemia, CML , and MDS , evaluation for malignant disease  includes a bone marrow aspirate and biopsy  for pathology and 
cytogenetics . A bone marrow biopsy must  be performed no more than 44 days prior  to the initiation of conditioning.   (B) For lymphomas , bone marrow 
biopsy and/or imaging studies are appropriate for disease evaluation and  will be done acco rding to institutional practices .  Patients with lymphomas should 
undergo the same post -transplant testing as their pre -transplant evaluation  for matter of subsequent comparison.   Imag ing studies must be done no more than 
60 days prior to patient randomiza tion.   
5Pregnancy test must be performed < 30 days before the start of the transplant conditioning regimen. Pregnancy test is required for females of child -bearing 
potential and may be performed per institutional practices.  
6GVHD assessments performed weekly from Day 7 until Day 84 post-transplant, and then at Days 98, 180, 270 and 365. The GVHD assessment will include a 
review of all abnormalities experienced during the entire assessment period  and the highest grade  for each abnormality during the assessment period will be 
recorded on the Acute GVHD form  and the Follow -up/Chronic GVHD form in eClinical .  The Chronic GVHD Provider Survey will record GVHD symptoms 
present in the last week (whether attributed to GVHD or not ) and must be completed by a clinician on the day of the assessment.  
7The toxicity assessment will include a review of all toxicities experienced during the entire assessment period  and the highest grade  for each toxicity during 
the assessment period will be recorded on the Toxicity form in eClinical.  
8Chimerism may be evaluated in bone marrow, whole blood or blood cell fractions, including CD3 and CD33 or CD15 fraction , according to institutional 
practice . The actual measurement dates may be within +/ - 7 days  of the recommended time points.  
9The pre -conditioning  baseline sample must be collected prior to the initiation of the transplant conditioning regimen  and pre -antibiotic prophylaxis .  For 
patients, stool samples at Pre -Conditioning, Day 0, Day 7, Day 14, Day 21, and Day 28 are mandatory .  Starting day 35 through day 77, then at day 98, 180, 
270, 1 year, and 2 years , the stool samples  are optional .  Weekly urine sample collection for microbiome assays starting Pre -conditioning through Day 270, then 
at 1 year, and 2 years are ALL OPTIONAL .   Pre-transplant donor samples are to be collected from those donors who have signed the Mi -Immune cons ent.  
 
10Height is only required at baseline.  It is not required to be repeated at the other time points.  
11The related donor’s CBC needs to be collected at the same time as the scheduled Mi -Immune research samples and reported in Adv antage eClinical from those 
donors who have signed the Mi -Immune consent.  
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-5 4.6.2 Pre-transplant Evaluations  
The following observations must be completed within 60 days prior to  patient randomization , or 
74 days prior to initiation of conditioning regimen  unless otherwise indicated .  
• History, physical examination, height and  weight.  
• Karnofsky  performance status  
• HCT -Specific Comorbidity Index  score.  
• CBC with differential and platelet count, serum creatinine, bilirubin, alkaline 
phosphatase, AST and  ALT.    
• Infectious disease titers should be performed per institutional guidelines and may 
include : CMV antibody, Hepatitis panel (HepA Ab, HepB SAb, HepB SAg, HepB Core 
Ab, HepC Ab), herpes simplex virus, syphilis, HIV and HTLV I/II antibody, and 
varicella zoster.  
• EKG and LVEF – can be performed within 90 days prior to patient randomization.  
• Pulmo nary function tests, including DLCO and FEV1  - can be performed within 90 
days prior to patient randomization.  
• HLA typing of patient and donor.  HLA typing can be performed at any time prior to 
randomization . 
• Sibling donors must be HLA typed for HLA -A and -B at intermediate (or 
higher) resolution, and -DRB1 at high resolution using DNA -based typing.  
• Unrelated donors must be HLA typed for HLA -A, -B, -C and -DRB1 at high 
resolution using DNA -based typing.  
• Disease evaluation for patients with  acute leukemia, CML or MDS includes a bone 
marrow aspirate and biopsy for pathology and cytogenetics. A bone marrow biopsy 
must  be performed no more than 44 days prior  to the initiation of conditioning.  
• Disease evaluation for patients with lymphomas inclu des imaging studies for matters of 
comparison post -transplant, the types of which may be determined according to the 
center’s institutional practices. Imaging studies must be done no more than 60 days 
prior to patient randomization.  
• Chest X -ray or chest  CT. 
• Pregnancy test per institutional practices for females of child -bearing potential. NOTE: 
pregnancy test must be performed no more than 3 0 days prior to randomization  
and must be repeated if not within 30 days prior to the initiation of conditioning.   
• Patient  Reported Outcomes (PRO) to be completed by English or Spanish speaking study 
patients. 
• Pre-transplant donor and recipient samples for post -transplant chimerism  studies.  
• Related d onor and recipient b lood, urine and stool  samples for Mi-Immune study  
(Appendix J). CBCs need to be collected at the same time as the scheduled Mi -Immune 
research samples.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-6  
4.6.3 Post-transplant Evaluations  
The following observations will be made according to Table 4. 6B: 
• History and physical exam to assess GVHD and other morbidity weekly through Day 84 
post-transplant, then at Days 98, 180, 270  and 365 post -transplant. GVHD will be 
monitored in accordance with BMT CTN guidelines as specified in the BMT CTN 
Technical Manual  of Procedures (BMT CTN MOP). GVHD assessments weekly from 
Day +7 through Day +84 post-transplant, and then at Days 98, 180, 270  and 365 post - 
transplant.  
• Assessment for toxicities at Days 28, 56, 98, 180, 270  and 365 post-transplant.  
• CBC with differential  performed at least three times a week from Day 0 until ANC at 
least 500/μL for 3 consecutive measurements over 3 days and platelet count at least  
20,000/μL for 3 days without platelet transfusion in the prior 7 days (while hospitalized 
only) after nadir is reached. Thereafter, CBC weekly until Day 84 post-transplant, then 
at Days 98, 180, 270 , 365 and 730 post-transplant .  CBCs need to be collected at the 
same time as the sche duled Mi -Immune research samples . 
• Serum creatinine, bilirubin, alkaline phosphatase, ALT and AST, twice a week until 
hospital discharge and then weekly until Day 84 post-transplant, then at Days 98, 180, 
270 and 365  post-transplant.  
• Chimerism studies perfo rmed at Days 28 and 98 post-transplant. Chimerism may be 
evaluated in bone marrow, whole  unfractionated  blood or blood cell fractions, including 
CD3 and CD33 or CD15 fraction. The actual measurement dates may be within +/ - 7 
days of the recommended time  points. (see Appendix B)  
• Disease evaluation of the malignant disease at Days 98 and 365 post -transplant: For acute 
leukemia, CML and MDS this includes a bone marrow aspirate and biopsy for pathology 
and cytogenetics. For lymphomas this includes imaging studies, which will be done 
according to institutional practices and the same as prior to transplant, for matter of 
comparison.  
• Data on occurrence of  Grade 2 and 3  infections and recorded as per the BMT CTN 
Technical MOP.  
• Blood, urine and stool sam ples for Mi-Immune study  to be collected Days 7, 14, 21, 28, 
35, 42, 49, 56, 63, 70, 77, 84, 98, 180, 270, 365 and 730. ( see Appendix J)  
• Patient Reported Outcomes (PRO) to be completed by English or Spanish speaking study 
participant  at Days 98, 180 and 365.  The CIBMTR Survey Research Group will contact 
patients via email, phone or mail to collect the PRO instruments online, or on paper.  The 
Survey Research Group will notify the transplant center if a patient’s contact information 
has changed or if  they find through follow -up that the patient has died.  
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-7 4.6.4 Criteria for Forms Submission  
Criteria for timeliness of submission for all study forms are detailed in the Data Management 
Handbook and User’s Guide. Forms that are not entered into Advantage eClin ical within the 
specified time will be considered delinquent. A missing form will continue to be requested either 
until the form is entered into the Advantage eClinical and integrated into the eClincal  master 
database, or until an exception is granted and entered into the Missing Form Exception File, as 
detailed in the Data Management  Handbook.  
4.6.5 Reporting Patient Deaths  
Recipient death information must  be entered into Advantage eClinical within 24 business hours 
of knowledge of the patient’s death. If the ca use of death is unknown at that time, it need not be 
recorded at that time. However, once the cause of death is determined, the form must be updated 
in Advantage eClinical.  
4.7 Adverse Event Reporting Requirements  
4.7.1 Definitions  
Adverse Event: An Adverse Event (A E) is defined as any unfavorable and unintended sign  
(including an abnormal laboratory finding), symptom, or disease that is temporally associated with 
the use of a medical treatment or procedure regardless of whether it is considered related to the 
medica l treatment or procedure.  
Expectedness : An adverse event can be Expected or Unexpected  
• Expected adverse events are those that have been previously identified as resulting from 
administration of the agent. For the purposes of this study, an adverse event is considered  
expected  when it appears in the current adverse event list, the Investigator’s Brochure, 
the package insert or is included in the informed consent document as a potential  risk. 
• Unexpected adverse events are those that vary in nature, intensity or frequency from 
information in the current adverse event list, the Investigator’s Brochure, the package 
insert, or when it is not included in the informed consent document as a potential  risk. 
 
Serious Adverse Eve nt: A serious adverse event (SAE), as defined by per 21 CFR 312.32, is 
any adverse event that results in one of the following outcomes, regardless of causality and 
expectedness:  
• Results in death  
• Is life -threatening.  Life-threatening means that the person was at immediate risk of 
death from the reaction as it occurred, i.e., it does not include a reaction which 
hypothetically might have caused death had it occurred in a more severe form.  
• Requires or prolongs inpatient hospitalization  (i.e., the event requir ed at least a 24 -
hour hospitalization or prolonged a hospitalization beyond the expected length of stay). 
Hospitalization admissions and/or surgical operations scheduled to occur during the 
study period, but planned prior to study entry are not considered SAEs if the illness or 
disease existed before the person was enrolled in the trial, provided that it did not 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-8 deteriorate in an unexpected manner during the trial (e.g., surgery performed earlier than 
planned).  
• Results in persistent or significant disabilit y/incapacity.  Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions.  
• Is a congenital anomaly or birth defect;  or 
• Is an important medical event  when, based upon appropriate medical judgment, it may 
jeopardi ze the participant and require medical or surgical intervention to prevent one of 
the outcomes listed above. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home; blood 
dyscrasias or co nvulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.  
 
Medical and scientific judgment should be exercised in deciding whether expected reporting is 
also appropriate in situations other than those listed above.  For example, important medical events 
may not be immediately life threatening or result in death or hospitalization but may jeopardize 
the patient  or may require intervention to prevent one of the outcomes listed in the definition above  
(eg, suspected transmission of an infectious agent by a medicinal product is considered a Serious 
Adverse Event). Any event is considered a Serious Adverse Event if it is associated with clinical 
signs or symptoms judged by the investigator to have a sign ificant clinical impact.  
4.7.2 BMT CTN Adverse Event Reporting Guidelines  
Adverse event reporting will be consistent with BMT CTN procedures (BMT CTN Administrative 
Manual of Procedures, Chapter 6). It is BMT CTN policy that AEs must be reported even if the 
investigator is unsure whether a relationship exists between the adverse event and the use of study 
treatment.   
Unexpected, serious adverse events (SAEs) will be reported through an expedited AE reporting 
system via Advantage  eClinical . Unexpected, life -threatening and fatal SAEs must be reported 
within 24 hours of knowledge of the event.  All other unexpected SAEs must be reported 
within three business days of knowledge of the event.  Events entered in Advantage  eClinical  
will be reported using NCI’s Common Terminology Criteria for Adverse Events (CTCAE) 
Version 5.0.  
Expected AEs will be reported using NCI’s Common Terminology Criteria for Adverse Events 
(CTCAE) Version 5.0 at regular intervals as defined on the Form Submission Schedule , including 
calendar -driven case report forms (e.g., Toxicity and GVHD) or event -driven case report forms 
(e.g., Relapse/Progression, Infection, and Death) . Any expected life -threatening SAE not 
collected on another study form must be reported through the exp edited AE reporting 
system via Advantage  eClinical . 
The Data and Safety Monitoring Board will receive summary reports of all unexpected SAEs on 
a semi -annual basis.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 4-9 4.8 CIBMTR Data Reporting  
Centers participating in BMT CTN trials must register pre - and post -transplant outcomes on all 
consecutive hematopoietic stem cell transplants done at their institution during their time of 
participation to the Center for International Blood and Marrow Transplant Research (CIBMTR).  
Registration is done using procedures and forms of the Stem Cell Transplant Outcomes Database 
(SCTOD). (Note: Federal legislation requires submission of these forms for all US allotransplant 
recipients.) Enrollment in BMT CTN 1703 must be indicated on the SCTOD pre -transplant 
registration form. Ad ditionally, CIBMTR pre - and post - transplant Comprehensive Report 
Forms must also be submitted for all patients enrolled on this trial. CIBMTR forms will be 
submitted directly to the CIBMTR at the times specified on the Form Submission  Schedule.  
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-10 CHAPTER 5  
5 STATISTICAL CONSIDERATIONS  
5.1 Study Design  
The study is designed as a Phase III randomized, open label, multicenter trial to compare 
PTCy/Tac/MMF versus Tac/MTX for GVHD prophylaxis in patients with controlled malignant 
disease receiving an allogeneic PBSC transplant after a RIC regimen. The primar y endpoint is 
GRFS at 1 year. The target enrollment is 428 patients  in total , with  214 patients on each of  the two 
treatment arms.  
Of note, all statistical considerations for the Mi -Immune study are addressed in Chapter 5 of 
Appendix J.  
5.1.1 Accrual  
It is estim ated that 36 months of accrual will be necessary to enroll the targeted sample size with 
an accrual rate of approximately 12 patients per month.  Both Core and Affiliate Centers will enroll 
patients on this study.  Accrual will be reported by race, ethnicity, gender, and age.  
5.1.2 Randomization  
All patients will be randomized within 14 days prior to the initiation of conditioning therapy.  
Randomization will be performed in a 1:1 ratio using random block sizes for the two arms.  
Randomization will be stratified by centers and by disease risk using Disease Risk Index ( DRI 
Low, Intermediate and High). The DRI level “High” will include patients classified as both “High” 
and “Very High”.  
5.1.3 Primary Endpoint  
The primary endpoint is GRFS as a time to event endpoint  from the time of randomization . All 
transplanted patients will be followed for the primary endpoint for one year; however,  the primary 
endpoint will be analyzed as a time to event endpoint. The primary analysis will be done using the 
intent -to-treat principle.  
5.1.4 Primary Hypothesis  
The primary null hypothesis is that the hazard ratio between PTCy/Tac/MMF vsTac/MTX  for 
GRFS endpoint  is equal to one versus an alternative hypothesis that the hazard ratio not equal to  
one. A hazard ratio equal to one indicates no difference between the two treatments, while a hazard 
ratio less than one implies that the hazard  of GRFS is lower for patient s receiving PTCy/Tac/MMF 
compared with  those in the Tac/MTX patient group. A hazard ratio greater than one would indicate 
an opposite treatment effect. This null hypothesis will be tested using a two-sided significance 
level of 5% 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-11 5.2 Sample Size and Power Con siderations  
Sample size and power considerations are based on the comparison of PTCy/Tac/MMF to 
Tac/MTX using a Cox proportional hazards model.  We assume an accrual period of 36 months 
and a 12 -month follow -up period with a 5% drop -out rate . We further ass ume that the drop -out 
rate is exponentially distributed and that the GRFS endpoint matches  the results of the BMT CTN 
1203 trial control  group . The survival probabilities for GRFS are based on data collected from the 
BMT CTN 1203 study. Therefore, a sample  size of 428 patients ( 214 per arm) is required to 
sufficiently maintain a two-sided type I error of 5% while providing 90% statistical power for a 
two-sided test to detect a HR of 0.66.   
5.3 Interim Analysis and Stopping Guidelines  
The study will consist of one interim analysis for efficacy after the required total number of events 
is reached in all evaluable patients for the primary endpoint to be reviewed by the NHLBI -
appointed Data and Safety Monitoring Board (DSMB). An interim analysis for effi cacy will be 
cond ucted after reaching a total of  147 events,  at a 60% information fraction. The final analysis 
will be conducted when the targeted number of events of 244 occurs, or 1 year after the last patient 
is randomized . Policies and composition of t he DSMB are described in the BMT CTN’s Manual 
of Procedures.  
5.3.1 Interim Analysis for Efficacy  
Analyses will be performed as described below for the primary endpoint.  At the interim analysis 
time point, a Z test for comparing the two treatments will be compar ed to the critical values shown 
in Table 5.3A . All patients with follow -up post randomization prior to the time of the interim 
analyses will be used to compute this statistic.  If the test statistic is outside the continuation range, 
the DSMB will discuss t he continuation of the trial.  Should the DSMB stop the trial for efficacy, 
all patients receiving the inferior treatment arm will be switched to the superior  treatment arm 
where the study will proceed until the targeted sample size for Mi-Immune  is reached.   
Efficacy stopping rules are based on Wang and Tsiatis boundary family with shape parameters 
P=1.44, A=0, R=0 and G= 1.9618 .25 Higher values of P, with A and R fixed at zero, and G fixed at 
1.9618  will cause the group sequential test to be increasi ngly conservative at the earliest analyses 
times. This boundary corresponds approximately to a hazard ratio less than 0.5918 or greater than 
1.6898 and  Z statistic s less than -3.1710  or greater than 3.1710, respectively . A P -value less than 
0.00152  at the interim analysis  would indicate a statistically significant result.  
 
 
 
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-12 Table 5.3A: Efficacy Stopping Thresholds with Type I Error 0.05,  
Power 90% and an Effect Size of 15% or Hazard Ratio 0.66  
Analysis 
Time  Information 
Fraction  Total  
Cumulative  
Sample S ize Under  
Alternative  
 Cumulative Events  
Under  
Alternative  Hazard Ratio  
Efficacy  
Boundary  Z-Statistic  
Efficacy  
Boundary  Cumulative  
Type I Error  
    Lower  Upper  Lower  Upper   
Interim  0.60 334 147 0.5918  1.6898  -3.1710  3.1710  0.152%  
Final  1.00 428 244 0.7777  1.2858  -1.9618  1.9618  5.000%  
 
 
5.3.2 Operating Characteristics of the Design  
The statistical power to reject the null hypothesis under various treatment effect sizes using the Z 
test for comparing treatments is shown in Table 5.3A. This table shows that the target sample size 
of 428 patients has 90% power to detect a 0.66 hazard ra tio. 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-13 Table 5. 3B: Summary of Operating Characteristics  
Hazard 
Ratio  Corresponding 
Approximate Effect Size 
for GRFS Endpoint  Expected 
Number of 
GRFS Events  Overall  
Cumulative 
Power  Probability of 
Stopping Early at 
Interim Analysis  
0.57 20% 186 99.24% 0.5897 
0.66 15% 219 90.00 % 0.2548 
0.68 14% 224 85.28 % 0.2005 
 0.72 12% 232 72.66 % 0.1179 
0.76 10% 237 57.17 % 0.0652  
1.00 0.0 243 5.00% 0.0015  
 
5.3.3 Guidelines for Safety Monitoring  
Monitoring of a key safety endpoint will be conducted monthly, and if rates significantly exceed 
pre-set thresholds, the NHLBI will be notified in order that the DSMB can be advised.  Policies 
and composition of the DSMB are described in the BMT CTN's Manual of Procedures.  The 
stopping guidelines serve as a trigger for consul tation with the DSMB for additional review and 
are not formal “stopping rules” that would mandate automatic closure of study enrollment.  
Toxicity, adverse events, and other safety endpoints will be monitored regularly and reported to 
the DSMB at each meeti ng and sooner if there are concerns.  
The key safety endpoint for this study is Day 100 mortality.  The rate of mortality will be monitored 
up to Day 100 post -randomization separately in each of the two treatment arms.  The expected 
probability of Day 100 mortality after a reduced intensity conditioning transplant is 10 -15%, based 
on CIBMTR data.  Each month, the null hypothesis that the Day 100 mortality rate is less  than or 
equal to 15% is tested  separately in each treat ment arm using an extension of the  sequential 
probability ratio test (SPRT) for censored exponential  data—See Appendix C for more details on 
SPRT.  
This sequential testing procedure conserves type I error at 5% across all of the monthly 
examinations for a treatment arm. The censored exponential SPRT can be represented  graphically . 
At each monthly examination, the total patient time at risk  is plotted against the cumulative number 
of events . The continuation region of the SPRT is defined by two parallel line s. Only the upper 
boundary will be used for monitoring to protect against excessive Day 100 mortality.  If the 
cumulative number of events  falls above the upper boundary, the SPRT rejects the null hypothesis, 
and concludes that there are more events than pr edicted by the total time at risk . Otherwise, the 
SPRT continues until enrollment reaches the target sample size of 214 patients per arm.  
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-14 This procedure assumes a n exponential distribution for the  time until death during the first 100 
days and censors follow -up time at Day 100.  Only deaths that occur on or before the patient has 
been followed  for 100 days are counted.  Total time on study is computed as time from 
randomization  to death or to Day 100, whichever comes first, summed for all patients on study.  A 
SPRT contrasting 15% versus 25% Day 100 mortality rate results in decision boundaries with a 
common slope of 0. 8005  and a n upper intercept of 4. 8015  with nominal type I and II errors of 
5.8% and 10%, respectively. Because of truncation of the SPRT at a finite sample size the actual 
type I and II errors will usually be lower than nominal levels.  
The actual operating characteristics of the truncated test were determined in a simulation study 
that as sumed uniform accrual of 428 participant s over a 36-month period . The  actual error rates 
are shown in Table 5.3 C. 
Table 5. 3C: Operating Characteristics of the Sequential Probability R atio Test  
for Day 100 Mortality with 100,000 Simulation Replicates  
True Day 100 Mortality Rate  15% 17% 20% 23% 25% 
Probability Reject Null  0.050 0.152  0.474 0.813 0.935 
Mean Month Stopped  36 34 27 19 15 
Mean Number of Day 100 Mortality Events  31 33 31 25 20 
Mean Number of Patients Enrolled  207 195 157 108 82 
 
For example, the testing procedure rejects the null hypothesis in favor of the alternative 5 .0% of 
the time when the true Day 100  mortality rate is 15%, and 93.5% of the time when the rate is 25%. 
This corresponds to a type I error rate of  = 0.050 and a type II error rate of  = 0.065. When the 
true Day 100  mortality rate is 25%, on average, the DSMB will be consulted 15 months after 
opening, when 20 events have been observed in 82 patients.  
5.4 Demog raphic and Baseline Characteristics  
Demographics and baseline characteristics will be summarized for all patients.  Characteristics to 
be examined are: age, gender, race/ethnicity, performance status, primary disease, disease -specific 
risk categories, DRI, hematopoietic cell transplant comorbidity index (HCT CI), donor type and 
HLA matching, donor/recipient CMV status, donor/recipient sex match, donor/recipient ABO 
match, and conditioning regimen.  Between group comparisons will be performed for continuous 
variables via a Kruskal -Wallis test and for categorical variables, via the chi -square test.  
5.5 Analysis Populations  
5.5.1 Primary Population  
The intention -to-treat population will serve as the population for the primary analysis. All 
randomized patient s will be incl uded in this population. Patient s will be included in the treatment 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-15 group to which they are randomized. Intention -to-treat population consists of all randomized 
patient s whether or not treatment was administered.  
5.5.2 Safety Population  
The safety analysis population in this study will comprise of all patients “as treated” in the study. 
This population will be used for the analysis of safety data. The “as treated” population consists 
of all randomized patient s who received a  HCT with one of the two randomized GVHD 
prophylaxis regimens . Patient s will be included in the treatment group corresponding to the study 
treatment (GVHD prophylaxis) they actually received for the analysis of safety data using the “as 
treated” population. For most patients this will be the treatment group to which they are 
randomized.  
5.5.3 Tran splant Population  
The transplant population will include all patients who have received  a transplant after 
randomization.  
5.6 Analysis of Primary Endpoint  
Kaplan -Meier curves along with 95% confidence intervals will be constructed to estimate GRFS 
probabilities at 1 year for each treatment group.  The primary analysis will consist of a comparison 
of GRFS in the ITT population  by treatment arm based on a multi variate Cox regression model.  
The following covariates  will be adjusted for  in the regression model: age, DRI, planned RIC 
regimen , donor type/HLA matching , and planned use of post-transplant maintenance therapy . A 
significance level of 0.05 ( two-sided) will be used to test the null hypothesis of no difference 
between the treatments.  Ninety -five percent confidence intervals for the hazard ratio of the 
PTCy/Tac/MMF treatment will also be constructed.   
5.7 Analysis of Secondary Endpoints  
5.7.1 Acute GVHD  
Incidence of acute GVHD grade II -IV and grade III -IV at Days 100, 180  and 1 year  will be 
estimated with 95% confidence intervals for each treatment group - using the cumulative incidence 
estimate, treating death prior to aGVHD as a competing event. Comparison of cumulative 
incidence will be done using Gray’s test. A multivariate Cox regression model for the cause -
specific hazard of aGVHD will be used to compare the treatment groups, after adjustment for 
baseline characteristics as described for the primary endp oint. 
5.7.2 Chronic GVHD  
Incidence of chronic GVHD at 1 year will be estimated with 95% confidence intervals for each 
treatment group using the cumulative incidence estimate, treating death prior to chronic GVHD as 
a competing event.  Comparison of cumulative inc idence will be done using Gray’s test. A 
multivariate Cox regression model for the cause -specific hazard of chronic GVHD will be used to 
compare the treatment groups, after adjustment for baseline characteristics as described for the 
primary endpoint.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-16 5.7.3 Systemic Immunosuppression -Free Survival  
Proportions of patients alive, relapse free, and off immune suppression at 1 year will be described 
for each treatment group, along with 95% confidence intervals.  If there is substantial censoring 
prior to one year, mul tistate models will be constructed to estimate these probabilities.  Agreement 
between this endpoint and the primary endpoint of GRFS will be described using cross -tabulation 
frequencies and assessed using the Kappa statistic.   
5.7.4 Hematologic Recovery  
Probabil ities of neutrophil recovery by Day 28 and Day 100 will be described with 95% confidence 
intervals for each treatment group using the cumulative incidence estimate, treating death as a 
competing event.  Similarly, probabilities of platelet recovery by Day 6 0 and Day 100 will be 
described with 95% confidence intervals for each treatment group using the cumulative incidence 
estimate, treating death as a competing event.  These cumulative incidence curves will be compared 
using Gray’s test.  
5.7.5 Donor Cell Engraftmen t 
Donor chimerism at Day 28 and Day 100 after transplantation in each of the randomized treatment 
arms will be described numerically as median and range for those evaluable as well as according 
to proportions with full (>95%  donor cell ), mixed (5 .0-94.9% donor cells), graft rejection (<5%), 
or death prior to assessment of donor chimerism.  Incidence of secondary graft failure (chimerism 
<5% after initial donor cell engraftment) will be described for each arm using frequencies.  
Comparisons between quantitati ve donor chimerism will be done using Wilcoxon rank sum test, 
while comparisons between categorical donor chimerism groups will be done using chi -square 
tests.  
5.7.6 Disease Relapse or Progression  
Incidence of disease relapse or progression at 1 year will be est imated with 95% confidence 
intervals for each treatment group using the cumulative incidence estimate, treating death prior to 
disease relapse as a competing event.  A multivariate Cox regression model for the cause -specific 
hazard of relapse or progression  will be used to compare the treatment groups with the control 
group, after adjustment for baseline characteristics as described for the primary endpoint.   
5.7.7 Transplant -related Mortality  
Incidence of transplant -related mortality (TRM) at Days 100, 180  and 1 year will be estimated for 
each treatment group using the cumulative incidence estimate, treating disease relapse or 
progression as a competing event.  A multivariate Cox regression model for the cause -specific 
hazard of TRM will be used to compare the trea tment groups with the control group, after 
adjustment for baseline characteristics as described for the primary endpoint.   
5.7.8 Toxicity  
All Grade 3 -5 toxicities will be tabulated by grade for each randomized treatment arm, by type of 
toxicity as well as the pe ak grade overall.  Toxicity frequencies up to 1 year will be described for 
each time interval as well as cumulative over time.   
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page 5-17 5.7.9 Infections  
The number of infections and the number of patients experiencing infections will be tabulated for 
each randomized trea tment arm by type of infection, severity, and time period after transplant.   
5.7.10  Disease -free Survival  
Kaplan -Meier curves will be constructed to estimate 1 year disease free survival probabilities for 
each treatment group. A multivariate Cox regression model for the risk of death or 
relapse/progression will be used to compare the treatment groups, after adjustment for baseline 
characteristics as described for the primary endpoint.   
5.7.11  Overall Survival  
Kaplan -Meier curves will be constructed to estimate 1 year overall survival probabilities for each 
treatment group.  A multivariate Cox regression model for the risk of death will be used to compare 
the treatment group, after adjustment for baseline characteristics as described for the primary 
endpoint.   
5.7.12  Post-Transpla nt Lymphoproliferative Disease (PTLD)  
Probabilities of PTLD  at 1-year post transplant will be described with 95% confidence intervals 
for each treatment group using the cumulative incidence estimate, treating death as a competing 
event. These estimates will be compared between groups using Gray’s test.    
5.7.13  Patient -Reported Outcomes (PRO)  
Patient -Reported Outcomes will be measured at baseline then at Days 100, 180  and one year post 
HCT. Using a repeated measures model, we will compute PRO  composite scores and compare 
treatments after adjustment for baseline character istics as described for the primary endpoint.  
All patient s with at least one post  HCT PRO  assessment will be incorporated within the relevant 
repeated measures analysis, whether they completed or discontinued the study. Missing 
assessments will not be impu ted, as we  assume these  data are missing at random.  
5.8 Safety Analysis  
Adverse events will be graded according to the NCI Common Terminology Criteria for Adverse 
Events Version 5.0.   
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page A-1 APPENDIX A  
HUMAN SUBJECTS  
 
1. Subject Consent  
Candidates for the study will be identified as described in Chapter 4 of the protocol.  The Principal 
Investigator or his/her designee at each transplant center will contact the candidates, provide them 
with information about the purpose of the study and obtain voluntary consent  if the candidates 
agree to participate . The BMT CTN will provide a template of the consent form to each center.  
Each center will add their NMDP IRB -approved boiler -plate language to the consent and submit 
it for review by the NMDP  Internal  Review B oard (IRB).  The DCC will verify the adequacy of 
the consent forms prior to submission to the IRB.  The NMDP IRB will provide  evidence of IRB 
approval.  
 
2. Confidentiality  
Confidentiality will be maintained by individual names being masked and assigned a pat ient 
identifier code.  The code relaying the patient’s identity with the ID code will be kept separately at 
the center.  The ID code will be transmitted to the network.  
 
3. Participation of Women and Minorities  
Women and ethnic minorities and other populati ons will be included in this study.  Accrual of 
women and minorities at each center will be monitored to determine whether their rates of 
enrollment are reflective of the distribution of potentially eligible women and minorities expected 
from data reported to the CIBMTR and from published data on incidence of leukemia and 
lymphoma in these groups.  Centers will be notified if their rates differ significantly from those 
expected and asked to develop appropriate recruitment reports.  
Patients under the age of 18  years will not be eligible to enroll on this study.  Reduced Intensity 
Conditioning (RIC) is not a standard therapy for patients in this age group.   PBSC grafts are not 
used standardly in this age group for allogeneic transplants either.   
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page B-1  
 
 
 
 
 
 
 
APPENDIX B  
CHIMERISM  ASSESSMENT  
We will study the proportion of patients with full ( at least 95% or more ) or mixed (5 .0-94.9%) 
total donor chimerism or graft rejection ( less than 5% total donor chimerism) . 
 
Chimerism analysis will be performed according to institutional practice, with the following as 
prioritization for analysis : 
1. Sorted peripheral blood lymphocyte and myeloid populations  
2. Unsorted peripheral blood mononuclear cell populations  
3. Whole (unsorted) bone marrow  
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page C-1 APPENDIX C  
DERIVATION OF A SEQUENTIAL TEST STATISTIC FOR CENSORED 
EXPONENTIAL DATA  
 
Background – The Sequential Probability Ratio Test  
Let 
)(.,f be the density function for random variable X.  According to Neyman and Pearson, the 
most powerful test of 
o H =:0  versus
1 1:= H  decides in favor of 
1H  or 
0H if 
c Ln  or 
c Ln
, respectively, where 
=n
ii i n xf xf L );(/);(0 1   is the likelihood ratio, and 
c is 
determined to have the size 
 . When the sample size is not fixed in advance, further improvement 
is possible by using Wald’s Sequential P robability Ratio Test (SPRT).  The SPRT continues to 
sample as long as 
A LBn   for some constant 
A B 1 , stops sampling and decides in favor of 
1H
as soon as 
A Ln , and stops sampling and decides in favor of 
0H as soon as 
B Ln . 
 
The usual measures of performance of such a procedure are the error probabilities 
 and
 of 
rejecting 
0H when 
0= , and of accepting 
0H when 
1= , respectively, and the expected 
sample size 
)( )|( NE NEj j . Wald and Wolfowitz showed that among all tests, sequential or 
not, for which 
) reject (Pr0 0 H  and 
) reject (Pr0 1 H , and for which 
)(NEj  are finite, j=0,1, 
the SPRT with error probabilities 
  and 
 minimizes 
)(0NE  and 
)(1NE . If, in addition, the 
,...2,1xx
 are independent and identically distributed (i.i.d.) with density function 
),(xf , with 
monotone likelihood ratio in 
)(x , then any SPRT for testing 
0 against 
) (0 1   has non -
decreasing power function.  
 
For the SPRT with error probabilities 
 and
 , the SPRT boundaries are given approximately 
by 
/) 1(−=A  and 
) 1/(  − =B . The operating characteristics of the SPRT are given by 
) /()1 (),,,,()( )( )(
1 0  h h hB A A O − − =
 where 
)(h is the non -trivial solution to the equation 
=1 );( )),(/);(()(
2 1 dxxf xf xfh  
.  
 
The formula 
);(/] log)( log)]( 1[[();(     zEB OA O NE + − = provides the average sample number 
for an arbitrary 
 . The sample size distribution is very highly skewed, 
2)]([)( NE N Var  . Thus we 
will consider a truncated test with maximum sample size of 
0N  and simulate to obtain the 
operating characteristics of the test.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page C-2 Derivation of the SPRT for Uncensored Exponential Survival Times  
For example, we wish to construct a sequential test for the composite null hypothesis that the rate 
of TRM at 180 days is less than or equal to 5% versus the alternative hypothesis that it is greater 
than or equal to 5%.  For the derivation of the uncensored SPRT, we will require that the type I 
error of the test be less than 10%, and that the test provide 90% power to reject the null hypothesis 
under a specified alternative that the true rate is 10%.  A maximum sample size of 250 patients will 
be permitted.  
Let us assume that the s urvival times, 
nT TT ,...,,2 1 , are completely observed (uncensored) and are 
i.i.d. with exponential density function 
Te Tf −=),( . These assumptions will be relaxed to 
incompletely observed data subsequently.  In the exponential parameteri zation, a 180 -day survival 
rate of 95% translates into a mean survival of 9.747 years (
=0 .1026), and 90% translates into a 
mean survival of 4.746 years (
=1 .2107).  
The SPRT is derived with reference to a simple null a nd alternative hypothesis, in this case, 
= =o H :0
 .1026 versus
1 1:= H  = .2107.  However, since the log -likelihood ratio for the  
exponential, 
   − − − = −n
in
in
ii i i T n xf xf ) ()) log() (log( ),( log);( log0 1 0 1 0 1      , is a 
monotone function of 
n
iiT , the power of the test is non -decreasing in 
 . Thus the SPRT is a 
one-sided level .10 test of a composite null (
1026. :0 = o H  ) versus a composite alternative (
2107. :1 = o H 
), with power of 
90. 1 =−  at the selected alternative 
= =1  .2107.  
The SPRT can be represented graphically.  The continuation region is bounded by two parallel lines 
with common slope 
= − − ) log /(log) (0 1 0 1    0.150, and intercepts 
= − ) log /(log log0 1   A 3.05 
and 
= − ) log /(log log0 1   B -3.05 for the lower and upper bounds, respectively.  As each individual 
unit is put on trial and observed to fail, the current sample size, n, is plotted against the cumulative 
sum of failure times.  When this graph crosses the upper bou ndary, the null hypothesis is rejected.  
The maximum sample size of 250 patients requires that the SPRT be truncated.  We choose to 
truncate the SPRT by declaring that if the test has failed to terminate after 250 patients, that the 
null hypothesis will be a ccepted.  Since the probability that the untruncated SPRT would reject the 
null at a sample size of 250 is negligible, it makes little difference how the final boundary value is 
selected, and this rule is chosen for simplicity.   
Derivation of a Modified SPR T for Censored Exponential Data  
The assumption of uncensored exponential survival times is flawed.  However, we consider it 
reasonable to assume the hazard for TRM is constant over the first 180 days post -transplant, and 
we will restrict our attention to th is time interval.  Furthermore, it is not practical to conduct a 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page C-3 clinical study by putting each individual on trial, and waiting until that individual is observed to 
fail. We relax our assumptions as follows.  Firstly, each individual’s time on study will be  computed 
as time from transplant to failure, or to the 180 day time point, whichever comes first.  Secondly, 
we will put individuals on trial as soon as they become available, without waiting for the previous 
individual to fail.  
Let us consider the impact of relaxing these assumptions one at a time.  In a fixed sample size trial 
with uncensored exponential failure times, mean survival time is estimated by the sample mean of 
the failure times, or total time on study divided by the number of individuals enroll ed. When 
censoring is introduced, the estimate becomes the total time on study divided by the number of 
observed (non -censored) failures.  This suggests that in an exponential SPRT test modified to 
incorporate censoring, we replace the observed failure time s, 
nT TT ,...,,2 1 , with censored failures 
times, 
nx xx ,...,,2 1 , and the current sample size, 
n , with the number of observed failures, 
d .  
Now we relax the second assumption, and  put individuals on trial as soon as they become available, 
without waiting for the previous individual to fail.  Assume that three years are required for accrual 
of 250 patients to the study, and that the final analysis takes place 180 days after the last patient is 
entered.  Putting all of this together, we propose a modified truncated SPRT, where at any interim 
time point, 
s , ranging from 0 to 3 years 180 days, the number of observed failures, d(s), is plotted 
against the sum of observ ed time on study, 
n
iisX)( . In practice, monitoring will be scheduled 
monthly after the start of enrollment to the study.  A further modification to the SPRT was to only 
use the upper boundary for stopping since the primary focus of the monito ring is to protect against 
unacceptable 180 -day TRM rates.  
Operating Characteristics of the Modified SPRT Test for Censored Exponential Data  
Recall that the uncensored SPRT targeted a drop in TRM -free survival at Day 180 from 95% to 
90%, with type I and II errors of 10% and 10%.  Since only the upper boundary is used for 
monitoring, the continuation region of the test was bounded above by a line with a slope of 0.150 
and intercept of 3.05.  In our example, the sample size is large enough that the reduction in power 
due to truncation of the test is negligible compared to the increase in power because the modified 
SPRT, lacking a lower boundary, cannot stop early to “accept” the null hypothesis.  In order to 
maintain type I error, we raise the upper boundary to  make it harder to cross.  Under the further 
assumption of uniform accrual over a three year period, and monthly interim analyses over the 
course of the study, the operating characteristics of the modified SPRT were obtained from a 
simulation study.  These s imulation show that an intercept of 4.02, corresponding to setting 
parameters 
  and 
 to 10% and 10%, result in empirical type I and II error rates of 10% and 
10%.   
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page C-4 Table C.1: Operating Characteristics of Sequential Testing Procedures  
  from a Simulation Study with 100,000 Replications  
True 180 -Day Rate  5% 10%  
Probability Reject Null  0.095  0.903  
Mean Month Stopped  41.0 20.2 
Mean # Endpoints in 180 days  11.8 11.6 
Mean # Patients Enrolled  240.8  135.4  
 
While the motivation for this testing procedure is largely heuristic rather than theoretical, the 
simulation results validate the approach.  When the true rate of TRM on or before Day  180 was 
5%, the test crossed the lower boundary in 9484 of 100,000 replications, for an estimated type I 
error rate of 9.5%.  When the true rate of TRM on or before Day 180 was 10%, the test failed to 
cross the boundary in the in 9742 of 100,000 replicatio ns, for an estimated type II error rate of 
9.7%.  In this setting, on average, the boundary will be crossed at 20.2 months.  
It is interesting to note that the SPRT derived above for exponential failure times with censoring 
at 180 days, has operating charact eristics which are similar to those of a more traditional SPRT, 
derived for binomial variates with success probability equal to the 180 day failure rate.  Using time 
to failure rather than a simple binary indicator of failure, leads to little improvement in  power when 
failure times are censored relatively soon after entry on study.  We speculate that if the constant 
hazard rate over the first 180 days were high, the exponential test would reject faster than the 
binomial test, but have not conducted simulation  studies to demonstrate this.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page D-1 APPENDIX D  
KARNOFSKY PERFORMANCE STATUS SCALE  
 
Index  Specific Criteria  General  
100 Normal, no complaints, no evidence of 
disease.  
 Able to carry on normal activity; 
no special care needed.  
90 Able to carry on normal activity, minor signs 
or symptoms of disease.  
80 Normal activity with effort, some signs or 
symptoms of disease.  
70 Care for self, unable to carry on normal 
activity or to do work.  Unable to work, able to live at 
home and care for most personal 
needs, varying amount of 
assistance needed.  60 Requires occasional assistance from others but 
able to care for most needs.  
50 Requires considerable assistance from others 
and frequent medical care  
40 Disabled, requires special care and assistance.  Unable to care for self, requires 
institutional or hospital care or 
equivalent, disease may be rapidly 
progressing.  
 30 Severely disabled, hospitalization indicated, 
but death not imminent.  
20 Very sick, hospitalization necessary, active 
supportive treatment necessary.  
10 Moribund  
0 Dead  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page E-1 APPENDIX E  
HCT -SPECIFIC COMORBIDITY INDEX SCORE  
 
Comorbidities  Definition  Score  
Migraine/headache   0 
Osteoporosis   0 
Osteoarthritis   0 
Hypertension   0 
Gastrointestinal  Including inflammatory bowel disease  0 
Mild pulmonary  DLCo and/or FEV 1 >80% or  
Dyspnea on moderate activity  0 
Mild renal  Serum creatinine 1.2 -2 mg/dl  0 
Endocrine   0 
Bleeding   0 
Coagulopathy  Deep venous thrombosis or pulmonary embolism  0 
Asthma   0 
Arrhythmia   1 
Myocardial  Coronary artery disease, congestive HF, history of 
medically documented MI, EF 50% 1 
Mild hepatic  Chronic hepatitis, Bilirubin >ULN - 1.5 X ULN, or 
AST/ALT >ULN -2.5XULN  1 
Cerebro -vascular 
accident  History of transient ischemic attack or cerebro -vascular 
accident  1 
Morbid obesity   1 
Diabetes  Requiring treatment  1 
Depression/anxiety   1 
Infection  Requiring continuation of treatment after Day 0  1 
Rheumatologic  SLE, RA, polymyositis, mixed CTD, polymyalgia 
rheumatica  
 2 
Moderate pulmonary  DLCo and/or FEV 1 66-80% or  
Dyspnea on slight activity  2 
Peptic ulcer  Patients who have required treatment  2 
Moderate -severe renal  Serum creatinine >2 mg/dl, on dialysis, or prior renal 
transplantation  2 
Valvular heart disease  Except mitral valve prolapse  3 
Prior solid tumor  Requiring treatment with chemotherapy  3 
Moderate -severe hepatic  Liver cirrhosis, Bilirubin >1.5 X ULN, or AST/ALT 
>2.5XULN  3 
Severe pulmonary  DLCo and/or FEV 1 65% or  
Dyspnea at rest or requiring oxygen  3 
Total score is the sum of all comorbidities present at time of transplantation.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page F-1 APPENDIX F  
2014 REFINED DISEASE RISK INDEX24 
Participating sites to use column labeled as “New DRI Group” to report DRI of enrolled 
patient . 
 
 
 

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-1 APPENDIX G  
DIAGNOSIS AND SEVERITY SCORING FOR ACUTE AND CHRONIC GVHD  
 
1. Acute GVHD organ staging  and grading22 
 
 
 
 
 
 
 
  

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-2 2. Grading of Chronic GVHD (NIH Criteria)23 
 
 
 
Organ scoring of chronic GVHD. ECOG indicates Eastern Cooperative Oncology Group; KPS, Karnofsky Performance Status; LPS, Lan sky 
Performance Status; BSA, body surface area; ADL, activities of da ily living; LFTs, liver function tests; AP, alkaline phosphatase; ALT, alanine 
aminotransferase; ULN, normal upper limit. *Weight loss within 3 months. Skin scoring should use both percentage of BSA invol ved by disease 
signs and the cutaneous features scal es. When a discrepancy exists between the percentage of total body surface (BSA) score and the skin feature 
score, OR if superficial sclerotic features are present (Score 2), but there is impaired mobility or ulceration (Score 3), th e higher level should b e 
used for the final skin scoring. To be completed by specialist or trained medical providers. **Lung scoring should be perform ed using both the 
symptoms and FEV1 scores whenever possible. FEV1 should be used in the final lung scoring where there is discre pancy between symptoms and 
FEV1 scores.  
  

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-3  
  

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-4  
  

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-5 3. Categories of Acute and Chronic GVHD  
 
Categories of Acute and Chronic GVHD  
Category  Time of 
Symptoms 
after HCT  Presence 
of Acute 
GVHD 
Features  Presence of 
Chronic 
GVHD 
Features*  
Acute GVHD    
Classic acute GVHD  ≤100 d  Yes No 
Late-onset acute GVHD  >100 d  Yes No 
Chronic GVHD    
Classic chronic GVHD  No time 
limit  No Yes 
Overlap syndrome  No time 
limit  Yes Yes 
*As defined in section 4 (below)  
  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page G-6 4. Signs and Symptoms of Chronic GVHD23 
 

Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page H-1 APPENDIX H  
PATIENT REPORTED OUTCOME  QUESTIONS  
BMT CTN 1703 Hemorrhagic Cystitis questions  
During the past 7 days, how many days did you see blood in your urine ? 
1. No days  
2. 1 day  
3. 2 days  
4. 3-5 days  
5. 6-7 days  
How often did you feel like you needed to empty your bladder right away or else you would have 
an accident?  
1. Never  
2. One time during the past 7 days  
3. 2-6 times during t he past 7 days  
4. Often once a day  
5. More than once a day  
 
PROMIS questions  
[GISX38 ] During the past 7 days, h ow many days did you have loose or watery stools?  
1. No days  
2. 1 day  
3. 2 days  
4. 3-5 days  
5. 6-7 days  
 
[GISX42] How often did you feel like you needed to empty your bowels right away or else you 
would have an accident?  
1. Never  
2. One time during the past 7 days  
3. 2-6 times during the past 7 days  
4. Often once a day  
5. More than once a day  
 
[PFA6 ] Does your health now limit you in bathing or dressing yourself ? 
1. Not at all  
2. Very little 
3. Somewhat  
4. Quite a lot  
5. Cannot do  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page H-2 [PFA53 ] Are you able to run errands and shop?  
1. Without any difficulty  
2. With a little difficulty  
3. With some difficulty  
4. With much difficulty  
5. Unable to do  
[PFA21 ] Are you able to go up and down stairs at a normal pace ? 
1. Without any difficulty  
2. With a little difficulty  
3. With some difficulty  
4. With much difficulty  
5. Unable to do  
PSRPSAT06r1] I am satisfied with my ability to do things for my family.  
1. Not at all  
2. A little bit  
3. Somewhat  
4. Quite a bit  
5. Very much  
[SRPSAT49r1 ] I am satisfied with my ability to perform my daily routines . 
1. Not at all  
2. A little bit  
3. Somewhat  
4. Quite a bit  
5. Very much  
[SRPSAT09r1] I am satisfied with my ability to do the work that is really important to me 
(include work at home).  
1. Not at all  
2. A little bit  
3. Somewhat  
4. Quite a bit  
5. Very much  
6.  
LEE CHRONIC GVHD SYMPTOM SCALE questions  
On a scale of 0 to 4, indicate how much you have been bothered by the following problems in the 
past month : 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page H-3 Skin:  
• Abnormal skin color  
• Rashes  
• Thickened skin  
• Sores on skin  
• Itchy skin  
 
Eyes and Mouth:  
• Dry eyes  
• Need to use eye drops frequently  
• Difficulty seeing clearly  
• Need to avoid certain foods due to mouth pain  
• Ulcers in mouth  
• Receiving nutrition from an intravenous line or feeding tube 
 
Breathing:  
• Frequent cough  
• Colored sputum  
• Shortness of breath with exercise  
• Shortness of breath at rest  
• Need to use oxygen  
 
Eating and Digestion:  
• Difficulty swallowing solid foods  
• Difficult swallowing liquids  
• Vomiting  
• Weight loss  
 
Muscles and Joints:  
• Joint and muscle aches  
• Limited joint movement  
• Muscle cramps  
• Weak muscles  
 
Energy:  
• Loss of energy  
• Need to sleep more/take naps  
• Fevers  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page H-4  
Mental and Emotional:  
• Depression  
• Anxiety  
• Difficulty sleeping  
 
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page I-1 
  APPENDIX I  
REFERENCES  
1Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, et al. Blood stem 
cells compared with bone marrow as a source of hematopoietic cells for allogeneic 
transplantation. IBMTR Histocompatibility and Stem Cell Sources Workin g Committee and the 
European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000 Jun 
15;95(12):3702 -9. 
2Ringden O, Pavletic SZ, Anasetti  C, Barrett AJ, Wang T, Wang D, et al. The graft -versus -
leukemia effect using matched unrelated donors is not superior to HLA -identical siblings for 
hematopoietic stem cell transplantation. Blood. 2009 Mar 26;113(13):3110 -8. 
3Lee SJ, Klein J, Haagenson M, Baxter -Lowe LA, Confer DL, Eapen M, et al. High -resolution 
donor -recipient HLA matching contributes to the success of unrelated donor marrow 
transplantation. Blood. 2007 Dec 15;110(13):4576 -83. 
4Shaw BE, Gooley TA, Malkki M, Madrigal JA, Begovich AB, Horow itz MM, et al. The 
importance of HLA -DPB1 in unrelated donor hematopoietic cell transplantation. Blood. 2007 
Dec 15;110(13):4560 -6. 
5den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout  JW, et al. Identification 
of a graft versus host disease -associated human minor histocompatibility antigen. Science. 
1995;268(5216):1476 -80. 
6Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, et al. Mismatches of minor 
histocompatibility antigens between HLA -identical donors and recipients and the development 
of graft -versus -host disease after bone marrow transplantation. N Engl J Med. 1996 Feb 
1;334(5):281 -5. 
7Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N, et al. Treatment of 
moderate/severe acute graft -versus -host disease after allogeneic bone marrow transplantation: 
an analysis of clinical risk factors and outcome. Blood. 1990;75:1024 -30. 
8Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, et al. A retrospe ctive 
analysis of therapy for acute graft -versus -host disease: secondary treatment. Blood. 
1991;77(8):1821 -8. 
9Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and 
cyclosporine compared with cyclosporine alone for prop hylaxis of acute graft versus host disease 
after marrow transplantation for leukemia. N Engl J Med. 1986;314:729 -35. 
10Fay JW, Wingard JR, Antin JH, Collins RH, Pi¤ero LA, Blazar BR, et al. FK506 (tacrolimus) 
monotherapy for prevention of graft -versus -host disease after histocompatible sibling allogeneic 
bone marrow transplantation. Blood. 1996;87:3514 -9. 
11Przepiorka D, Devine S, Fay J, Uberti J, Wingard J. Practical considerations in the use of 
tacrolimus for allogeneic marrow transplantation. Bone Marrow  Transplant. 1999 
Nov;24(10):1053 -6. 
12Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing 
methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft -
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page I-2 
  versus -host disease after marrow  transplantation from unrelated donors. Blood. 2000 Sep 
15;96(6):2062 -8. 
13Brunstein CG, Fuchs EJ, Carter SL et al. Alternative donor transplantation after reduced intensity 
conditioning: results of parallel phase 2 trials using partially HLA -mismatched re lated bone 
marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282 -288.  
14Luznik L, Fuchs EJ, Chen AR et al. Post -transplantation high -dose cyclophosphamide (Cy) is 
effective single agent GVHD prophylaxis that permits prompt immune reco nstitution after 
myeloablative HLA matched related and unrelated bone marrow transplantation (BMT). Biology 
of Blood and Marrow Transplantation. 2007;13:4.  
15Luznik L, O'Donnell PV, Symons HJ et al. HLA -haploidentical bone marrow transplantation for 
hematologic malignancies using nonmyeloablative conditioning and high -dose, 
posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641 -650.  
16Raj, K., Streetly, M., Kazmi, M., Harringon, E., Getzendaner, L. C., Lee, S. J., and O'Donnell, P. 
V. Peripheral Blood Progenitor Cell (PBPC) Transplantation from Haploidentical Donors 
Following Reduced Intensity Conditioning (RIC) for High -Risk Hematologic  Malignancies. 
Biology of blood and marrow transplantation : journal of the American Society for Blood and 
Marrow Transplantation 18[2], S331. 2 -1-2012.  
17Bolaños -Meade J, Fuchs EJ, Luznik L et al. HLA -haploidentical bone marrow transplantation 
with posttr ansplant cyclophosphamide expands the donor pool for patients with sickle cell 
disease. Blood. 2012;120:4285 -4291.  
18Luznik L, Fuchs EJ. High -dose, post -transplantation cyclophosphamide to promote graft -host 
tolerance after allogeneic hematopoietic stem ce ll transplantation. Immunol Res. 2010;47:65 -77. 
19Ciurea SO, Mulanovich V, Saliba RM et al. Improved early outcomes using a T cell replete graft 
compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol 
Blood Marrow Transpl ant. 2012;18:1835 -1844.  
20Bashay A, Zhang MJ, McCurdy SR, St. Martin A, Argall T, Anasetti C, et al. Mobilized 
Peripheral Blood Stem Cells versus Unstimulated Bone Marrow as a Graft Source for T -Cell 
Replete Haploididentical Donor Transplantation Using Pos t-Transplant Cyclophosphamide. J 
Clin Oncol. 2017;35(26):3002 -9. 
21Mielcarek M, Furlong T, O’Donnell PV, Storer BE, McCune JS, Storb R, et al. 
Postransplantation cyclophosphamide for prevention of graft -versus -host disease after HLA -
matched mobilized blood  cell transplantation. Blood. 2016;127(11):1502 -8. 
22Harris AC, Young R, Decine S, et al. International, Multicenter Standardization of Acute Graft -
versus -Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD 
International Consort ium. Biology of Blood and Marrow Transplantation 2016;22:4 -10.  
23Jagasia MH, Hildegard TG, Arora M, et al. National Institutes of Health Consensus Development 
Project on Criteria for Clinical Trials in Chronic Graft -versus -Host Disease: I. The 2014 
Diagno sis and Staging Working Group Report. Biology of Blood and Marrow Transplantation; 
Journal of the American Society for Blood and Marrow Transplantation 2015;21:389 -401. 
24Armand P, Haesook TK, Logan B, et al. Validation and refinement of the Disease Risk I ndex for 
allogeneic stem cell transplantation. Blood 2014;123(23):3664 -3671  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page I-3 
  25Kittelson, J.M. and Emerson, S.S., 1999. A unifying family of group sequential test designs. Biometrics,  
55(3), pp.874 -882.26Belkaid Y and Hand TW. Role of the microbiota in immunity and 
inflammation. Cell 2014;157(1):121 -41. 
 
27Andermann TM, Peled  JU, Ho C, et al. The microbiome and hematopoietic cell transplantation: 
past, present, and future. Biol Blood Marrow Transplant 2018;24(7):1322 -40. 
28Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in 
patients receivi ng allogeneic stem cell transplantation: loss of diversity is associated with use of 
systemic antibiotics and more pronounced in gastrointestinal graft -versus -host disease. Biol 
Blood Marrow Transplant 2014;20(5):640 -5. 
29Weber D, Jenq RR, Peled JU, et al.  Microbiota disruption induced by early use of broad 
spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell 
transplantation. Biol Blood Marrow Transplant 2017;23(5):845 -852. 
30Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from 
graft -versus -host disease. Biol Blood Marrow Transplant 2015;21(8):1373 -83. 
31Shono Y, Docampo MD, Peled JU, et al. Intestinal microbiota -related effects on graft -versus -
host disease. Int J Hematol 2015;101(5): 428-37. 
32Peled JU, Devlin SM, Staffas A, et al. Intestinal microbiota and relapse after hematopoietic -cell 
transplantation. J Clin Oncol 2017;35(15):1650 -59. 
33Kashyap PC, Chia N, Nelson H, et al. Microbiome at the Frontier of Personalized Medicine. 
Mayo Clin Proc 2017;92(12):1855 -64. 
34Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiota transplantation for clostridium 
difficile infection: a systematic review. Ann Intern Med 2015;162(9):630 -8. 
35Kostic AD, Xavier RJ, and Gevers D. The microbiome in in flammatory bowel disease: current 
status and the future ahead. Gastroenterology 2014;146(6):1489 -99. 
36Wilkinson EM, Ilhan ZE, and Herbst -Kralovetz MM. Microbiota -drug interactions: impact on 
metabolism and efficacy of therapeutics. Maturitas 2018;112:53 -63. 
37Kroemer G and Zitvogel L. Cancer immunotherapy in 2017: the breakthrough of the 
microbiota. Nat Rev Immunol 2018;18(2):87 -88. 
38Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic 
hematopoietic stem cell transplantation. Front Immunol 2016;7:507.  
39Suessmuth Y, Mukherjee R, Watkins B, et al. CMV reactivation drives posttransplant T -cell 
reconstitution and results in defects in the underlying TCRbeta repertoire. Blood 2015;125:3835 -
50. 
40van Heijst JW, Ceberio I, Lipuma LB,  et al. Quantitative assessment of T cell repertoire recovery 
after hematopoietic stem cell transplantation. Nature medicine 2013;19:372 -7. 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page I-4 
   
41Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin -7 (CYT107) promotes 
T-cell recovery after a llogeneic stem cell transplantation. Blood 2012;120:4882 -91. 
 
42Meyer EH, Hsu AR, Liliental  J, et al. A distinct evolution of the T -cell repertoire categorizes 
treatment refractory gastrointestinal acute graft -versus -host disease. Blood 2013;121:4955 -62. 
 
43Emerson R, Sherwood A, Desmarais C, Malhotra S, Phippard D, Robins H. Estimating the rati o 
of CD4+ to CD8+ T cells using high -throughput sequence data. Journal of immunological methods 
2013;391:14 -21. 
 
44Wu D, Sherwood A, Fromm JR, et al. High -throughput sequencing detects minimal residual 
disease in acute T lymphoblastic leukemia. Science tra nslational medicine 2012;4:134ra63.  
 
45Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B 
lymphoblastic leukemia by high -throughput sequencing of IGH. Clinical cancer research : an 
official journal of the American Association f or Cancer Research 2014;20:4540 -8. 
 
46Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow 
cytometry and high -throughput sequencing for minimal residual disease detection in chronic 
lymphocytic leukemia: an European Res earch Initiative on CLL study. Leukemia 2016;30:929 -
36. 
 
47Honda K and Littman DR. The microbiota in adaptive immune homeostasis and disease. 
Nature 2016;535(7610:75 -84. 
48Gopalakrishnan V, Spencer CN, Nezi  L, et al. Gut microbiome modulates response to anti -PD-
1 immunotherapy in melanoma patients. Science 2018;359(6371):97 -103. 
49Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD -1-based 
immunotherapy against epithelial tumor s. Science 2018;359(6371):91 -97.  
50Moissev  I, Pirogova O, Alyanski A, et al. Graft -versus -Host Disease Prophylaxis in Unrelated 
Peripheral Blood Stem cell Transplantation with Post -Transplantation Cyclophosphamide, 
Tacrolimus, and Mycophenolate Mofetil. B BMT 2016;22(6):1037 -1042.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Versio n 4.0 dated November 16, 2020  
Page J-1 
  APPENDIX J  
Mi-Immune  Study  
 
Page J-0 
  
Microbiome and Immune Reconstitution in Cellular 
Therapies and Hematopoietic Stem Cell Transplantation 
(Mi-Immune)  
 
BMT CTN Protocol 1801  
 
Principal Investigators  
Ami Bhatt, MD, PhD1 
Leslie S. Kean MD, PhD18 
Miguel -Angel Perales, MD3 
 
Companion  Study Protocol Team:
Merav Bar , MD2 
Brandi Bratrude , PNP, CCRP18 
Saurabh Chhabra , MD4 
Sung Choi , MD5 
William Clark , MD, MS6 
Suman R. Das , PhD7 
Mary Horowitz, MD, MS4 
Rob Jenq , MD8 
Rick Jones , MD9 John Levine , MD10 
Brent Logan, PhD4 
Hemant Murthy , MD12 
Armin Rashidi , MD, PhD13 
Marcie Riches , MD, MS14 
Wael Saber, MD, MS4 
Karamjeet Sandhu , MD15 
Ashley Spahn16 
Anthony Sung , MD17
 
Sponsored by the National Institutes of Health  
National Heart, Lung, and Blood Institute  
National Cancer Institute  
 
1Stanford University  
2Fred Hutchinson Cancer Research 
Center  
3Memorial Sloan Kettering Cancer 
Center  
4Medical College of Wisconsin  
5University of Michigan  
6Virginia Commonwealth University  
7Vanderbilt University  
                8MD Anderson Cancer Center  
9Johns Hopkins University  
 10Mount Sinai  
11Emmes  
12University of Florida  13University of Minnesota  
14University  of North Carolina  
15City of Hope  
16National Marrow Donor Program  
17Duke University  
18Boston Children’s Hospital  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-1 
   
 
 
CHAPTER 1  
1 BACKGROUND AND SIGNIFICANCE  
Allogeneic HCT is an effective treatment for patients with malignant and non -malignant 
hematologic  diseases. However, this treatment is complicated by high rates of morbidity and 
mortality limiting its broader a pplication. The leading causes of post -transplant morbidity and 
mortality include acute and chronic GVHD, relapse and infectious disease.  The goal of the trial is 
to apply a systems biology approach to understanding the mechanisms driving these complications, 
such that evidence -based treatment strategies can be devised. Results of this study may also inform 
the development of accurate and predic tive surrogate markers of clinically relevant endpoints that 
may be informative for future BMT clinical trial design.  
The sample repository and molecular and clinical databases established through the trial will be 
made available to the biomedical communi ty and are expected to facilitate studies that will 
establish the utility of molecular biomarkers for risk assessment, diagnosis and monitoring, and 
allow more rational treatment strategies to be developed for patients undergoing allogeneic HCT.  
These stu dies are also likely to provide mechanistic insights and to identify new therapeutic targets 
leading to development of more targeted and effective therapies.  
The goal of this protocol is several -fold:  First, it is to test the primary hypothesis that the 
engraftment stool microbiome diversity (determined by 16s rRNA sequencing analysis of the 
sample closest after, but within 14 days of neutrophil engraftment) predicts 1 -year non -relapse 
mortality in patients undergoing reduced -intensity allogeneic HCT.  Sec ond, it is to perform 
additional analyses on patient samples to answer key questions concerning: a) the impact of the 
stool microbiome on transplant outcome as well as the impact of transplant on the microbiome and 
the associated downstream impact on patie nt health; and b) reconstitution of the T cell repertoire 
after transplant.  Third, it is to establish a cohort of biologic samples collected prospectively from 
patients treated on BMT CTN 1703 that will be a shared biospecimen resource for conducting 
future allogeneic HCT correlative studies.  The resulting dataset will become an additional 
resource generated by the trial and will be made available to the biomedical community. Mi -
Immune is designed to link molecular data and biospecimens with high quality clinical phenotype 
and outcomes data to identify risk factors for development and severity of key complications after 
allogeneic HCT.  
To achieve this goal, patients and donors will be recruited and consent will be obtained at the time 
that they enroll on BMT CTN protocol 1703.  Samples will be collected: (1) from patients and 
donors pre -transplant; and, (2) from patients post -transplant on a calendar -driven schedule through 
the first year post -HCT.  Shared clinical data will be collected in the context of the primary 
transplant protocol, BMT CTN 1703, and Mi -Immune -specific data will be collected using Case 
Report Forms (CRFs).  Additiona l clinical data will be available from data submitted to the Center 
for International Blood and Marrow Transplant Research (CIBMTR) using the CIBMTR CRFs.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-2 
  CHAPTER 2  
2 STUDY DESIGN  
2.1 Study Overview  
In this study, we will collect stool, urine, and blood biospecimens, as well as detailed clinical data 
on infections and antibiotic exposures in an attempt to understand the microbial and immune 
recovery predictors of HCT outcomes. This study will form the correlative science arm of the BMT  
CTN 1703 study (PRO GRESS III), which will compare two acute graft -versus -host disease 
(aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post -transplant 
cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced 
intensity c onditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation.  
2.2 Hypothesis and Objectives  
2.2.1 Hypothesis  
The engraftment stool microbiome diversity (determined within 14 days after neutrophil 
engraftment) predicts 1 -year non -relapse mortality.  
2.2.2 Objectives  
Primary Objective : 
The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome 
diversity (determined by 16s rRNA sequencing analysis of the sample closest after, but within 14 
days of neutrophil engraftment ) predicts 1 -year non -relapse mortality in patients undergoing 
reduced -intensity allogeneic HCT.  
Secondary Objectives : 
Microbiome, Infection, and Antimicrobial E xposure:  
1) Association of engraftment microbiome diversity with development of aGVHD, cGVHD, 
and overall survival (corrected for GVHD prophylaxis).  
2) Association of baseline microbiome diversity with development of aGVHD, cGVHD, and 
overall survival (corrected for GVHD  prophylaxis).  
3) Effect of GVHD prophylaxis on microbiome diversity: Difference in the level of 
microbiome diversity detected at 6, 12, and 24 months in the 2 arms.  
4) Association of microbiome oligodomination at the time of engraftment (>30% of 
microbiome bein g a single operational taxonomic unit) with increased subsequent risk of 
bloodstream infection.  
5) Association of volume of antimicrobial exposure (number and duration of drugs) in first 
30 days after transplant with rates of aGVHD, cGVHD, and overall surviva l. 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-3 
  6) Association between urine metabolites (such as indoxyl sulfate) at the time of engraftment 
and rate of acute GVHD.  
Immune Repertoire:  
1) Effect of GVHD prophylaxis on TCR diversity: Difference in the level of TCR diversity 
detected at 3, 6, 12 and 24 month s in the 2 arms.  
2) Effect of TCR diversity at 3 months, 6 months, 12 months and 24 months  on subsequent 
non-relapse mortality, overall survival, and relapse, using landmark analyses and time -
dependent covariates.  
Biorepository:  
1) To establish a cohort of biol ogic samples and a linked clinical and molecular dataset from 
patients treated on BMT CTN 1703. The product of this study will be a shared biospecimen 
and data resource for conducting future allogeneic HCT mechanistic studies.  Examples of 
future explorato ry objectives that can be addressed with this biorepository are the 
following:  
Exploratory Objectives : 
1) Effect of antibiotic use (length of exposure, anaerobic sparing vs. not) on level of 
microbiome diversity at 6, 12, and 24 months.  
2) Effect of aGVHD and/or  its treatment on microbiome at 6, 12 and 24 months.  
3) Effect of cGVHD and/or its treatment on microbiome at 12 and 24 months.  
4) Effect of CMV and BK reactivation on TCR diversity at 3, 6, 12 and 24 months.  
5) Effect of patient age on TCR diversity at 3, 6, 12, and 24 months.  
6) Effect of donor age on TCR diversity at 3, 6, 12, and 24 months.  
7) Effect of aGVHD and/or its treatment on TCR diversity at 3, 6, 12 and 24 months.  
8) Effect of cGVHD and/or its treatment on TCR diversity at 12 and 24 months.  
9) Correlation of micro biome diversity and TCR diversity at 3, 6, 12, and 24 months.  
2.3 Eligibility Criteria for Enrollment  
 
The primary intention of the Mi -Immune protocol is to co -enroll patients on BMT CTN 1703.  
Patient inclusion and exclusion criteria are those of BMT CTN 1703.   Related and unrelated donors 
must be at least 18 years of age .  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-4 
  2.4 Treatment Plan  
The conditioning, GVHD prophylaxis, and supportive care are described in BMT CTN 1703.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-5 
  CHAPTER 3  
3 STUDY ENDPOINTS AND DEFINITIONS  
3.1 Primary Endpoint  
The primary endpoint is non -relapse mortality within one year.  This endpoint is defined according 
to the BMT CTN 1703 protocol.  This primary endpoint will be associated with the engraftment 
stool microbiome diversity (grouped by tertiles) for the primary  analysis of this study.   
3.2 Secondary Endpoints  
3.2.1 Clinical Endpoints  
Standard transplant endpoints and clinical outcomes, with the exception of infections and 
antimicrobial use, will be collected according to BMT CTN 1703, including long -term follow -up 
data c ollection through CIBMTR. The endpoi nts collected on BMT CTN 1703 include acute 
GVHD, chronic GVHD, non -relapse mortality, relapse, death and cause of death.   In addition, a 
feasibility endpoint (i.e., proportion of samples successfully collected on schedu le), and 
exploratory analyses of donor/recipient pairs will be included.  
3.2.2 Infection  
Data on infections and antimicrobial agent administration occurring through Day 365 will be 
collected specifically for patients  with Mi -Immune samples collected .  The incidence of definite 
and probable viral, fungal and bacterial infections will be tabulated.  The infections will be reported 
using the BMT CTN Advantage eClinical data reporting system.  
3.2.3 Correlative endpoints  
3.2.3.1  Microbiome  
The microbiome w ill be analyzed in two ways:  
First, the microbiome taxonomic diversity will be evaluated using 16S ribosomal RNA amplicon 
sequencing. Data will be generated per standard protocols, as previously described.5 Resultant 
sequencing data will be quality filtered, adapter sequences will be trimmed, and sequences will be 
analyzed using the QIIME pipeline.6 Shannon diversity will be calculated, as previously 
described.7  
Second, urinary indoxyl sulfate has been used  as a biomarker of microbiome composition.8 We 
will measure urinary indoxyl sulfate using liquid chromatography followed by mass spectrometry, 
as previously describe d.9 
3.2.3.2  T cell Repertoire  
T cell repertoire will be analyzed using next generation sequencing o n the Adaptive 
Biotechnologies ImmunoSEQ platform.  PBMCs from patients will be collected at 3, 6, 12 and 24 
months post HCT.  TCR diversity will be assessed using the inverse Simpson's diversity index 
(1/Ds), which sums the frequency of each clonotype1. 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-6 
  CHAPTER 4  
4 PATIENT EVALUATION  
4.1 Pre-transplant Evaluations  
All pre -transplant evaluations occur as dictated by BMT CTN 1703.  The data will be captured in 
the BMT CTN 1703 forms and not re-entered for Mi -Immune.   
Additional Pre -transplant requirements f or Mi -Immune to be collected no sooner than 7 days prior 
to the start of conditioning regimen:  
1. Specimen Collection: Urine, stool, and blood will be collected pre -conditioning (Day -14 
to Day -7) and pre -infusion (Day -1 to Day 0).   Please note that stool  sample collection at 
pre-conditioning is MANDAT ORY and urine sample collection  is OPTIONAL .   
2. A CBC will be performed pre -conditioning (Day -14 to Day -7) and pre -infusion (Day -1 
to Day 0).  
3. Infection data collection at baseline.  
 
4.2 Post-transplant Evaluations  
1. For all enrolled HCT patients, the empty bag or syringe in which the stem cell product was 
infused will be retrieved by the study team and sent to the Central Reference Laboratory at 
ambient temperature where it will be washed to obtain donor cells for analysis.  
2. Toxicities associated with specimen collection for Mi -Immune will be collected and 
reported on days 28, 56, 98, 180, 270, and 365 post -transplant.  All other toxicities will be 
reported for BMT CTN 1703.  
3. Specimen collection (blood, urine, and stool) for microbiome assays will occur weekly 
starting on day 0 through day 77 (through day 84 for blood), then at day 98, day 180, day 
270, 1 year, and 2 years.    
• Weekly stool sample collection for microbiome assays starting  Day 0 weekly 
through Day 28 is MANDATORY.   
• Weekly stool sample collection for microbiome assays starting day 35 through 
day 77 , then at day 98, 180, 270, 1 year, and 2 years are OPTIONAL.   
• Weekly urine sample collection f or microbiome assays  starting Pr e-conditioning 
through Day 270, then at 1 year, and 2 years are ALL OPTIONAL .   
4. A CBC will be performed weekly from  day 0 through day 77 (through day 84 for blood) , 
then day 98, 180, 270, 365, And 730.  
5. Infection data : This will occur every 14 days from day 0 until day 98, then on day 180, 
270, and 365 post -transplant.  
6. Antimicrobial medications:  Specific medications including route of administration, start 
date, and stop date will be collected every 14 days from day 0 to  day 98. Medications prior 
to start of conditioning and on day 180, 270, and 365 post -transplant will be listed with 
route of administration for the 7 days prior to the form date.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-7 
   
 
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-8 
  Table 4. 2: Patient  and Donor  Evaluations  
 
  Pre-
conditioning 
(Day -14 to -7) Pre-
infusion 
(Day -1 to 
0) 0 7 
+ 3 14 
+ 3 21 
+ 3 28 
+ 3 35 
+ 3 42 
+ 3 49 
+ 3 56 
+ 3 63 
+ 3 70 
+ 3 77 
+ 3 84 
+ 3 98 
+ 7 180 
+ 
28 270 
+ 
28 365 
+ 
28 730 
+ 
60 
Patient 
Data  CBC  X X  X X X X X X X X X X X X X X X X X 
Infections  X  X  X  X  X  X  X  X X X X X  
Antimicrobial 
medications  X  X  X  X  X  X  X  X X X X X  
Toxicities        X    X     X X X X  
Patient 
Samples  Peripheral 
Blood  X*** X  X X X X X X X X X X X X X X X X X 
Urine1 X*** X  X X X X X X X X X X X  X X X X X 
Stool2 X*** X  X X X X X X X X X X X  X X X X X 
Related  
Donor 
Samples  CBC   X*                   
Peripheral 
Blood   X*                   
Urine   X*                   
Stool   X*                   
Hematopoietic 
Stem Cell 
Product Cells   
 X**                  
Unrelated 
Donor 
Samples  Hematopoietic 
Stem Cell 
Product Cells    X**                  
*Pre-donation.  
**Empty bag or syringe in which the stem cell product was infused . 
***Samples should be collected Pre -conditioning, pre -antibiotic prophylaxis on Day -14 to Day -7.  
1 Weekly urine sample collection for microbiome assays starting Pre -conditioning through Day 270, then at 1 year, and 2 years are ALL OPTIONAL  
2 Weekly stool sample collection for microbiome assays at Pre-conditioning, Pre -infusion /Day 0 weekly through Day 28 is MANDATORY.  Weekly stool  sample 
collection for microbiome assays starting day 35 through day 77, then at day 98, 180, 270, 1 year, and 2 years are OPTIONAL.   
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-9 
    
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-10 
  4.3 Collection of Research Samples  
Blood, stool, urine and biopsy research samples will be collected in this study. The majority of 
study samples will be collected on a calendar driven schedule. Based on historical experience with 
BMT CTN 1202, we anticipate high compliance (1202 calendar -driven samples were collected at  
a rate of 96% completeness).  
4.3.1  Study Blood Draws  
For transplant patients, the blood sample collections will occur at baseline (defined as pre -
conditioning, pre -antibiotic prophylaxis) at day -7 to day -14 prior to start of conditioning. Samples 
will then be collected weekly from day 0 (pre -infusion) through day 84 (+/ - 3 days), then on day 
+98 +/- 7 days,  day +180 +/ - 28 days, day +270 +/ - 28 days, day +365 +/ - 28 days, day +730 +/ - 
60 days as outlined in Table 4.2.  Related d onor samples  will be drawn prior to the peripheral 
blood stem cell collection .   
4.3.2     Stool Samples  
Stool samples will be collected according to standard operating procedures modified from the NIH 
Human Microbiome Project protocols. Briefly, samples will be stored at 4oC within 30 minutes of 
collection and then will be shipped to NMDP within 24 -48 hours. At NMDP, the samples will be 
aliquoted and stored at -80oC. Samples will be collected with and without preservative solutions 
to enable downstream DNA, RNA a nd mass spectrometry (metabolite and metaproteome) 
analysis. Selected centers with substantial microbiome sampling experience will collect and 
process samples for additional downstream transcriptome and volatile metabolite sampling, which 
requires rapid pr ocessing. For transplant patients, the stool  sample collections will occur at 
baseline (defined as pre -conditioning, pre -antibiotic prophylaxis) at day -7 to day -14 prior to start 
of conditioning. Samples will then be collected weekly from day 0 through d ay 77 (+/ - 3 days), 
then on day +98  +/- 7 days,  day +180 +/ - 28 days, day +270 +/ - 28 days, day  +365 +/ - 28 days, 
day +730 +/ - 60 days as outlined in Table 4.2.1 (see Laboratory Procedures Table  for inpatient and 
outpatient stool collection schedule). 5 -10ml of stool will be obtained at each timepoint and placed 
into a sterile container. Stool sample will then be placed on ice (4oC) and transferred to the lab.  
4.3.3     Urine Samples  
Urine metabolites such as indoxyl sulfate are associated with GVHD and spe cific intestinal 
microbiome compositions. Urine collections will be performed according to the standard operating 
procedures outlined in the Laboratory Procedures Table . For transplant patients, the urine sample 
collections will occur at baseline (defined as pre -conditioning, pre -antibiotic prophylaxis) at day -
7 to day -14 prior to start of conditioning. Samples will the n be collected weekly from day 0 
through day 77 (+/ - 3 days), then on day +98  +/- 7 days, day +180 +/ - 28 days, day +270 +/ - 28 
days, day  +365 +/ - 28 days, day +730 +/ - 60 days as outlined in Table 4.2 . Samples will be placed 
at 4oC within 30 minutes of collection and for no more than 48 hours prior to aliquoting and deep 
freeze storage.  
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-11 
  CHAPTER 5  
5 STATISTICAL CONSIDERATIONS  
5.1 Study Overview  
This study is designed as a companion study to the BMT CTN 1703 Phase III randomized, open 
label, multicenter trial to compare PTCy /Tac/MMF versus Tac/MTX for GVHD prophylaxis in 
patients with controlled malignant disease receiving an allogeneic P BSC transplant after a RIC 
regimen. Patients enrolled on this study will be asked to provide additional study samples which 
will be linked with the clinical data collected on the parent protocol, in order to address specific 
research questions associated w ith those study samples and to provide banked samples for future 
studies.   
5.1.1 Accrual  
Accrual will occur in conjunction with the BMT CTN 1703 trial. The target enrollment of the 
parent trial is 428 patients; we plan to enroll approximately 70%, or n=300 pati ents, on this 
companion protocol.   It is estimated that 36 months of accrual will be necessary to enroll the 
targeted sample size. The study will remain open until the last recipient enrolled has been followed 
for two years post -transplant.  
5.1.2 Randomization  
Patients on the BMT CTN 1703 trial will be randomized at a ratio of 1:1 between the treatment 
arms; no further randomization will be done on this companion protocol.  
5.1.3 Primary Endpoint  
The primary endpoint for this study is non -relapse mortality within 1 yea r of transplant.   
5.1.4 Primary Objective  
The primary objective of Mi -Immune is to compare NRM within 1 year between groups defined 
by engraftment stool microbiome diversity.  Tertiles will be used to define 3 approximately equal 
sized groups.   
5.1.5 Sample Size and  Power Considerations  
The primary analysis will be done using a Fine and Gray model comparing the non -relapse 
mortality within 1 year between the three groups.  Non -relapse mortality by 1 year is expected to 
be approximately 15% overall based on BMT CTN 12 03 trial data. Using the method of Latouche 
(2004), we computed power to detect differences of 20% in the 1 year NRM between any two 
pairs of groups, using a Bonferroni adjusted type I error of 0.05/3 to account for pairwise 
comparisons2.  The table below shows various comparisons of this difference in NRM over an 
expected range of NRM for this protocol; the targeted sample size of 300 evaluable patients would 
have at least 85% power to detect a 20% difference in 1 year NRM between any two microbiome 
divers ity groups.   
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-12 
  Table: Power to detect 20% differences in 1 year NRM between any two microbiome diversity 
groups : 
 
NRM difference  Power  
5% vs. 25%  99% 
10% vs. 30%  93% 
15% vs. 35%  85% 
5.2 Interim Analysis and Pausing Guidelines  
As this is a non-interventional correlative study, no interim analyses will be included specifically 
as part of this protocol, separate from those used in BMT CTN 1703.  
5.3 Demographic and Baseline Characteristics  
Demographics and baseline characteristics will be described  for all patients and separately for each 
cohort.  Characteristics to be examined are: age, gender, race/ethnicity, performance status, 
primary disease, dis ease-specific risk categories, DRI, hematopoietic cell transplant comorbidity 
index (HCT CI), donor type and HLA matching, donor/recipient CMV status, donor/recipient sex 
match, donor/recipient ABO match, and conditioning regimen.  Between group comparisons will 
be performed for continuous variables via a Kruskal -Wallis test and for categorical variables , via 
the chi -square test.  Additionally, we will compare the distributions of these characteristics 
between patients with Mi-Immune samples collected vs. those enrolled on BMT CTN 1703 but 
who d id not provide  Mi-Immune  samples , to assess whether the Mi -Immune cohort appears 
representative of the larger trial.   
5.4 Analysis Populations  
5.4.1 Engraftment stool Microbiome Population  
All enrolled patients with an available engraftment stool microbiome diversity measure will be 
included in thi s population.  The primary analysis as well as secondary analyses focusing on the 
impact of the engraftment stool microbiome diversity on clinical outcomes will use this population.  
Outcomes are determined from the time of the engraftment stool sample col lection.  
5.4.2 Baseline Microbiome Population  
All enrolled patients with an available baseline stool microbiome diversity measure will be 
included in this population.  This population will be used for secondary analyses looking at the 
impact of baseline microbio me diversity on subsequent clinical outcomes.  Outcomes will be 
determined from the time of transplant.   
5.4.3 Landmark Microbiome Populations  
Various landmark microbiome populations will be used to examine the impact of microbiome 
diversity measures at that ti mepoint on subsequent clinical outcomes, or to compare microbiome 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-13 
  diversity measures at that timepoint between groups such as randomized GVHD prophylaxis 
strategy.  In each case, patients will be included if they are still at risk for the clinical outcome at 
the landmark time, and have an available microbiome diversity measure at that timepoint.  Clinical 
outcomes will be assessed starting at that landmark timepoint.  
5.4.4 Antimicrobial exposure population  
All enrolled patients with complete data collection on an timicrobial exposure within the first 30 
days and who are still at risk for the clinical outcome at day 30 will be included in this landmark 
antimicrobial exposure cohort.  The antimicrobial exposure population will be used to examine the 
impact of antimic robial exposure within 30 days on subsequent clinical outcomes.  Clinical 
outcomes will be assessed starting at 30 days.  
5.4.5 Landmark TCR diversity Populations.  
Various landmark TCR diversity populations will be used to examine the impact of TCR diversity 
measures at that timepoint on subsequent clinical outcomes, or to compare TCR diversity measures 
at that timepoint between groups such as randomized GVHD prophyl axis strategy.  In each case, 
patients will be included if they are still at risk for the clinical outcome at the landmark time, and 
have an available TCR diversity measure at that timepoint.  Clinical outcomes will be assessed 
starting at that landmark ti mepoint.  
5.5 Analysis Plan  
5.5.1 Analysis of the Primary Objective:  Compare NRM within 1 year between groups defined 
by engraftment stool microbiome diversity.   
This analysis will use the engraftment stool microbiome cohort.  Microbiome diversity will be 
separated into three groups based on tertiles for the primary analysis.  Non -relapse mortality will 
be summarized for each group using cumulative incidence with r elapse as a competing event and 
compared in a univariate manner between tertiles using Gray’s test.  A Fine and Gray model will 
be used to compare microbiome diversity groups after adjustment for baseline covariates; 
microbiome diversity as well as GVHD pr ophylaxis received will be forced into the model and 
stepwise selection will be used to identify additional variables associated with outcome.  
Interactions between GVHD prophylaxis received and microbiome diversity will be assessed.  A 
secondary analysis will further examine the functional form of the relationship between 
quantitative values of microbiome diversity and the subdistribution hazard for NRM using splines, 
and if appropriate, an optimal cutpoint will be determined.   
5.5.2 Analysis of the Secondary O bjectives  
Microbiome, Infection, and Antimicrobial Exposure:  
1) Association of engraftment microbiome diversity with development of aGVHD, cGVHD, 
and overall survival (corrected for GVHD prophylaxis).  
This analysis will use the engraftment stool microbiome co hort; diversity will be grouped 
by tertiles or if a more appropriate classification is identified in the primary analysis, that 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-14 
  may be used instead.  aGVHD (grade 2 -4 or 3 -4) and chronic GVHD (any or moderate -
severe) will be described in each group using c umulative incidence with death or relapse 
as a competing event, and compared between groups using Gray’s test.  Overall survival 
will be described using the Kaplan -Meier estimator and compared between groups using 
the log -rank test.  Multivariate models wi ll be constructed in a similar manner as for the 
primary endpoint using Fine and Gray models for aGVHD and cGVHD, and using Cox 
models for OS.   
2) Association of baseline microbiome diversity with development of aGVHD, cGVHD, and 
overall survival (corrected for GVHD prophylaxis).  
This analysis will use the baseline stool microbiome cohort; diversity at baseline will be 
separated into three groups based on tertiles for initial analysis. aGVHD (grade 2 -4 or 3 -4) 
and chronic GVHD (any or moderate -severe) will be  described in each group using 
cumulative incidence with death or relapse as a competing event, and compared between 
groups using Gray’s test.  Overall survival will be described using the Kaplan -Meier 
estimator and compared between groups using the log -rank test.  Multivariate models will 
be constructed in a similar manner as for the primary endpoint using Fine and Gray models 
for aGVHD and cGVHD, and using Cox models for OS.  We will also consider further 
examination of the functional form of the relation ship between quantitative values of 
baseline microbiome diversity and the risk of aGVHD, cGVHD, or death using splines, 
and if appropriate, an optimal cutpoint will be determined.  
3) Effect of GVHD prophylaxis on microbiome diversity: Difference in the level of 
microbiome diversity detected at 6, 12, and 24 months in the 2 arms.  
This analysis will use a series of landmark microbiome populations at each time point.  
Microbiome diversity will be compared between GVHD prophylaxis groups at each time 
point using M ann-Whitney tests; randomized GVHD prophylaxis groups will be used 
rather than GVHD prophylaxis received to maintain the ITT principle, however a 
secondary analysis using the GVHD prophylaxis received may also be performed.  
Transformation of diversity wil l be considered to induce normality.  If a normalizing 
transformation can be identified, analysis of covariance will be used to compare diversity 
at each time point, after adjustment for baseline diversity and other covariates; stepwise 
selection will be u sed to identify additional covariates associated with diversity.   
4) Association of microbiome oligodomination at the time of engraftment (>30% of 
microbiome being a single operational taxonomic unit) with increased subsequent risk of 
bloodstream infection.  
This analysis will use the engraftment stool microbiome population.  The number of 
bloodstream infections and the number of patients experiencing a bloodstream infection 
between engraftment and day 100 will be described by presence of microbiome 
oligodomin ation group.  Prevalence of active bloodstream infection will be described at 
subsequent visit times by microbiome oligodomination group, and compared using the chi -
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-15 
  square test.   Additional details on organisms will also be summarized.  Bloodstream 
infect ion density in the first 100 days will be computed as infection frequencies over 100 
patient days at risk. If there are sufficient numbers of bloodstream infection events in the 
first 100 days, multivariate regression analyses will be performed to examine the 
association between microbiome oligodomination and infection density, while adjusting 
for other relevant covariates. Proportional rates/means models will be used to model the 
infection density, with a robust variance estimator to account for within patient correlation; 
microbiome oligodomination and GVHD prophylaxis received will be forced into the 
model, and additional variables will be added using stepwise regression3. Interaction 
between microbiome oligodomination and GVHD prophylaxis received will b e assessed.  
5) Association of volume of antimicrobial exposure (number and duration of drugs) in first 
30 days after transplant with rates of aGVHD, cGVHD, and overall survival.  
This analysis will use the antimicrobial exposure population.  Volume of antimicr obial 
exposure will be computed by measuring the “daily defined dose” exposure for each 
individual. This value is calculated on a per antimicrobial basis. Each day that a patient is 
given a specific antimicrobial agent counts as one daily defined dose. Thu s, if a patient  
receives two different antimicrobials for one day each, the patient  has received 2 daily 
defined doses. Alternatively, if a patient  receives one antimicrobial for three days, the 
patient  has received 3 daily defined doses. For combination d rugs, such as 
trimethoprim/sulfamethoxazole, the daily defined doses will be calculated individually for 
each of the two active antimicrobial components of the combination therapy4. Volume of 
antimicrobial exposure will be dichotomized at the median.  aGVH D (grade 2 -4 or 3 -4) 
and chronic GVHD (any or moderate -severe) will be described in each group using 
cumulative incidence with death or relapse as a competing event, and compared between 
groups using Gray’s test.  Overall survival will be described using t he Kaplan -Meier 
estimator and compared between groups using the log -rank test.  Multivariate models will 
be constructed in a similar manner as for the primary endpoint using Fine and Gray models 
for aGVHD and cGVHD, and using Cox models for OS.   
6) Associati on between urine metabolites (such as indoxyl sulfate) at the time of engraftment 
and rate of acute GVHD.  
This analysis will use the engraftment stool microbiome cohort; urine metabolites at the 
time of engraftment will be dichotomized at the median.  aGVHD (grade 2 -4 or 3 -4) will 
be described in each group using cumulative incidence with death or relapse as a  competing 
event, and compared between groups using Gray’s test.  Multivariate models will be 
constructed in a similar manner as for the primary endpoint using Fine and Gray models 
for aGVHD.   
Immune Repertoire:  
1) Effect of GVHD prophylaxis on TCR diversity : Difference in the level of TCR diversity 
detected at 3, 6, 12 and 24 months in the 2 arms.  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-16 
  This analysis will use a series of landmark TCR diversity populations at each time point.  
TCR diversity will be compared between GVHD prophylaxis groups at each t ime point 
using Mann -Whitney tests; randomized GVHD prophylaxis groups will be used rather than 
GVHD prophylaxis received to maintain the ITT principle, however a secondary analysis 
using the GVHD prophylaxis received may also be performed.  Transformation  of diversity 
will be considered to induce normality.  If a normalizing transformation can be identified, 
analysis of covariance will be used to compare diversity at each time point, after adjustment 
for baseline diversity and other covariates; stepwise se lection will be used to identify 
additional covariates associated with diversity.   
2) Effect of TCR diversity at 3 months, 6 months, 12 months and 24 months on subsequent 
non-relapse mortality, overall survival, and relapse, using landmark analyses and time -
dependent covariates  
This analysis will use a landmark TCR diversity population at each time point.  TCR 
diversity will be dichotomized as above or below the median at each corresponding 
landmark time point, and cumulative incidence of non -relapse mortalit y and relapse will 
be estimated in each group, with relapse and death in remission respectively as competing 
risks.  Survival will be estimated in each group using Kaplan -Meier method.  We will 
examine the impact of TCR diversity over time as a time -depend ent covariate in Cox 
models for the cause specific hazard for NRM or relapse, or for the hazard of death; GVHD 
prophylaxis received will be forced into the models, and other covariates will be considered 
using stepwise variable selection.  We will also exp lore the functional form of the 
relationship between TCR diversity and outcome using splines and if appropriate will 
identify an optimal cutpoint.   
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-17 
  LABORATORY PROCEDURES  TABLE  
Study Subject  Research 
Sample Type  Time Points  Sample 
Quantity  Shipping 
Temperature 
to BMT CTN 
Biorepository   Sample Collection 
or Shipping 
Container  Processed Research 
Sample Material  Research Sample 
Material Aliquots  Storage 
Temperature  
Patient  
(N = 300)  Peripheral 
Blood  Pre-
conditioning, 
Day 14, 28, 98, 
180, 365, 730  39 mL  Insulated 
Ambient   5 mL Clot Tube  Serum  5 - 0.5 mL aliquots  
-80⁰ C 2 mL EDTA Tube  Whole Blood  2 - 1.0 mL aliquots  
32 mL in Sodium 
Heparin Tubes  Heparin Plasma  15 - 0.5 mL aliquots  
PBMC  ~3 - 5x106 / 1 mL 
aliqouts  LN 
Day 7, 21, 35, 
42, 49, 56, 63, 
70, 77, 84, 270  31 mL   Insulated 
Ambient  5 mL Clot Tube  Serum  5 - 0.5 mL aliquots  
-80⁰ C 2 mL EDTA Tube  Whole Blood  2 - 1.0 mL aliquots  
24 mL in Sodium 
Heparin Tubes  Heparin Plasma  15 - 0.5 mL aliquots  
PBMC  ~2 - 5x106 / 1 mL 
aliqouts  LN 
Pre-infusion  24 mL  Insulated 
Ambient   5 mL Clot Tube  Serum  5 - 0.5 mL aliquots  -80⁰ C 
24 mL in Sodium 
Heparin Tubes  Heparin Plasma  15 - 0.5 mL aliquots  
PBMC  ~2 - 5x106 / 1 mL 
aliqouts  LN 
Urine  Pre-
conditioning, 
Weekly Day 0 
to Day 77, Day 
98, 180, 270, 
365, 730  10-12 mL  2-8⁰ C  
Sterile Specimen 
Container  Urine - No Preservative  10 - 1.0 mL aliquots  -80⁰ C 
Stool  Pre-
conditioning, 
Weekly Day 0 
to Day 77, Day 
98, 180, 270, 
365, 730  10-12 mL  2-8⁰ C  Sterile Specimen 
Container  Stool - No Preservative  4 - 1 to 1.5 mL aliquots  
-80⁰ C 
Stool in RNAlater  2 - 1.5 mL processed 
aliquots  
  
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-18 
  Study 
Subject  Research 
Sample Type  Time Points  Sample 
Quantity  Shipping 
Temperature 
to BMT CTN 
Biorepository  Shipping 
Temperature 
to Leslie 
Kean Lab  Sample 
Collection or 
Shipping 
Container  Processed Research 
Sample Material  Research Sample 
Material Aliquots  Storage 
Temperature  
Related 
Donor  
(N= ~120)  Peripheral 
Blood  Pre-donation  41 mL  Insulated 
Ambient    5 mL Clot Tube  Serum  5 - 0.5 mL aliquots  
-80⁰ C 4 mL EDTA Tube  Whole Blood  4 - 1.0 mL aliquots  
32 mL Sodium 
Heparin Tubes  Heparin Plasma  15 - 0.5 mL aliquots  
PBMC  ~3 - 5x106 / 1 mL 
aliqouts  LN 
Urine  Pre-donation  10-12 mL  2-8⁰ C   Sterile Specimen 
Container  Urine - No Preservative  10 - 1.0 mL aliquots  -80⁰ C 
Stool  Pre-donation  10-20 mL  2-8⁰ C   Sterile Specimen 
Container  Stool - No Preservative  4 - 1 to 1.5 mL 
aliquots  
-80⁰ C Stool in RNAlater   
 2 - 1.5 mL processed 
aliquots  
 
All 
Donors            
(Will need 
protocol -
specific 
donor 
consent ) Hematopoietic 
Stem Cell 
Product Cells  Day 0  Product Bag 
or Syringe    2-8⁰ C Empty bag or 
syringe in which 
the stem cell 
product was 
infused  Viably Cryopreserved 
WBC  2-4 - 10x106 / 1 mL 
aliqouts  LN 
 
 
Blood and Marrow Transplant Clinical Trials Network  PROGRESS III - PTCY vs. TAC/MTX Protocol – 1703  
 Version 4.0 dated November 1 6, 2020  
 
Page J-0 
 Mi-Immune REFERENCES  
 
1Venturi, V., Kedzierska, K., Turner, S.J., Doherty, P.C. & Davenport, M.P. Methods  
for comparing the diversity of samples of the T cell receptor repertoire. J. Immun ol. Methods  321, 
182–195 (2007).  
2Latouche A, Porcher R, Chevret S (2004).  Sample size formula for proportional hazards 
modelling of competing risks.  Statistics in Medicine, 23:3263 -3274.  
3D. Lin, L. Wei, I. Yang, Z. Ying. Semiparametric regression for t he mean and rate functions of 
recurrent events. J Royal Statist Soc, 62 (2000), pp. 711 -730. 
 
4“Definition and General Considerations.” WHO Collaborating Centre for Drug Statistics 
Methodology , Norwegian Institute of Public Health, 
https://www.whocc.no/ddd/definition_and_general_considera/  
 
5Walters W, Hyde ER, Berg -Lyons D, et al. Improved bacterial 16S rRNA gene (V4 an d V4 -5) 
and fungal internal transcribed spacer marker gene primers for microbial community surveys. 
mSystems 2015;1(1):pii:e00009 -15. 
 
6Kuczynski J, Stombaugh J, Walter WA, et al. Using QIIME to analyze 16s rRNA gene 
sequences from microbial communities. Curr Protoc Microbiol 2012;Chapter 1.  
 
7Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on 
mortal ity following allogeneic hematopoietic stem cell transplantation. Blood 2014;124(7):1174 -
82. 
 
8Weber D, Oefner PJ, Hiergeist A, et al. Low urinary indoxyl sulfate levels early after 
transplantation reflect a disrupted microbiome and are associated with poo r outcome. Blood 
2015;126(14):1723 -8. 
 
9Zhu W, Stevens AP, Dettmer K, et al. Quantitative profiling of tryptophan metabolites in serum, 
urine, and cell culture supernatants by liquid chromatography -tandem mass spectrometry. Anal 
Bioanal Chem 2011;401(10):3 249-61. 
 